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The NHMRC Clinical Trials Centre at the University of Sydney conducts 
large multicentre investigator-initiated clinical trials, undertakes research 
with national and international trial groups, and contributes expertise to 
trials run by others. It also:
•	 takes a lead in proposing new directions for clinical research in 
Australia, particularly research aligned with national policy and clinical 
practice
•	 participates in translational research, from bench to bedside
•	 conducts methodological research in relation to clinical trials
•	 reviews and synthesises evidence from completed trials,  
and is at the forefront of developments in methods,  
such as prospective meta-analysis
•	 supervises postgraduate students in all of these areas
•	 offers postgraduate degrees in clinical trials research
•	 runs short courses to train people for Australian medical research.
The CTC also offers health technology and diagnostic test assessments, 
economic analyses, biostatistical design and analysis, and automated 
central randomisation services.
Core funding is provided by the NHMRC, and specific projects  
are funded by government, public and private institutions  
and the pharmaceutical industry. 
The CTC is at two sites in Camperdown in inner Sydney —  
the Medical Foundation Building on Parramatta Road and  
Chris O’Brien Lifehouse on Missenden Road.
This report covers the CTC’s achievements for 2014. 
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Directors’ report
Translational research
The Clinical Trials Centre collaborates 
with investigators on major trials and 
undertakes research and education 
in trials methodology. Increasingly, 
we are cooperating with diverse 
individuals and organisations in 
integrated translational research 
programs, which promise to reduce 
the time taken to render scientific 
discoveries into health outcomes. 
At the CTC, our research is planned 
with the full research pathway in 
mind. 
For example, in translational cancer 
research, the CTC works closely 
with its fellow members of Sydney 
Catalyst. This consortium brings 
together teams of researchers and 
clinicians from 6 institutes and 
8 hospitals, over 400 people in all, 
across New South Wales. Its research 
program encompasses three linked 
processes: T1, new knowledge from 
the laboratory or scientific setting; 
T2, testing in humans; and T3, 
using results of clinical studies in 
clinical practice and decision making.
The CTC is also a member of Sydney 
Research, a cluster of the major 
academic health institutions and 
tertiary hospitals in the Sydney health 
district, which form a broadly based 
precinct as a foundation for research 
growth and excellence. In 2014, 
the group established its strategic 
objectives, which include integrating 
research into every aspect of 
healthcare practice. 
Beyond the research pathway
The Australian Clinical Trials Alliance 
(ACTA) was formally launched at 
the ACTA Summit in March 2014. 
ACTA aims to be the national peak 
body to support and represent the 
investigator networks that conduct 
clinical trials in areas of need. The 
CTC has been deeply involved in the 
formation of ACTA and its current 
initiatives, including an international 
symposium to be held in Sydney 
in October 2015. Its longer-term 
objectives, include: first, bringing 
networks together to share expertise 
and develop strategies for boosting 
the capacity of Australian clinicians 
to answer important clinical 
questions; second, coordinating 
or supporting projects that help 
streamline the process of starting and 
running well-designed clinical trials; 
and third, driving policy development 
aimed at making ‘public-good’ clinical 
trials more central to health care in 
Australia in order to produce better 
health outcomes at lower cost.
Achievements by the CTC  
and its collaborators
Within the CTC itself, many individual 
projects make up a major research 
effort. Our main areas of interest 
are cancer, diabetes, cardiovascular 
disease and neonatal disorders, in a 
context of collaboration with others. 
In oncology, the process of choosing 
trial questions starts with concepts 
developed from real-world health 
care needs by networks of practising 
clinicians. The CTC works with major 
Australasian cancer investigator 
networks: gastrointestinal (AGITG), 
lung (ALTG), urogenital (ANZUP), 
gynaecological (ANZGOG), 
brain (COGNO) and and breast 
(ANZBCTG). These established 
CTC ExECuTivE
John Simes, director 
Anthony Keech, deputy director 
Wendy Hague,  
clinical trials program director 
Kim Russell-Cooper,  
general manager 
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groups have annual scientific 
meetings at which gaps in research 
are discussed and practicable 
responses developed, resulting in 
new rials that meet real-world needs. 
Diabetes is Australia’s fastest growing 
chronic disease and a focus of a large 
part of CTC’s research. The FIELD 
trial had shown that fenofibrate 
prevented progression of retinopathy, 
setting the scene for current studies 
in type 1 and type 2 diabetes: the 
FAME1-Eye trial (type 1 diabetes) 
and the work of the virtual Centre 
for Research Excellence in Health 
Services Research (type 2 diabetes). 
Clinical investigations are conducted 
in tandem with genetic and molecular 
experiments on the mechanisms and 
markers of diabetes risk.
In cardiovascular disease, the 
recent publication of the results 
of the INSPIREsstudy on aspirin 
to prevent thrombosis attracted 
worldwide media attention. INSPIRE, 
a prospective pooled analysis of the 
CTC’s ASPIRE trial and the Italian 
WARFASA study, gave us clear 
evidence that aspirin, an inexpensive 
treatment available everywhere, 
could prevent recurrent thrombosis in 
patients who cannot or do not want 
to take long-term anticoagulants. 
New multicentre trials in neonatology 
were launched in 2014. Among these, 
PAEAN is a trial of erythropoietin 
added to standard treatment for 
newborns with brain damage from 
birth hypoxia. It continues one of 
CTC’s research interests: improving 
the prospects of neonates at risk. The 
trial has been planned in cooperation 
with a parallel US trial, so if the 
treatment is found to be effective, 
the results will be evidence enough 
to rapidly translate into worldwide 
standard treatment.
CTC is now a leading source of 
experts in clinical trials methodology 
for Australia. We contribute to health 
research organisations throughout 
Australia and internationally though 
representation on committees 
of peak bodies such as ACTA and 
NHMRC, cancer council committees, 
trial steering and management 
committees, and executive roles on 
investigator networks. 
Our research methodology capability 
in biostatistics is widely shared 
through an active consultancy 
enterprise in which statisticians 
apply their knowledge to research 
programs in various Sydney hospitals, 
in addition to their extensive teaching 
commitments and educational 
masterclasses and workshops. 
They are among the CTC academics 
who teach the Master of Clinical 
Trials program and continue to be 
part of the national Biostatistics 
Collaboration of Australia’s 
postgraduate program.
The work of the health economics 
group is highly regarded, especially in 
an environment where demonstrated 
cost-effectiveness of health care 
interventions is essential.
The CTC has been active for many 
years in the Cochrane Collaboration’s 
work of obtaining and disseminating 
high-quality evidence to guide clinical 
decision making. Achievements by 
the Cochrane Breast Cancer Group 
were recognised when the Cochrane 
Library rated this team, based at the 
CTC, as one of its best and most 
productive groups. Their proficiency 
and relevance were reflected in the 
current high impact factor of their 
published reviews.
The Australian New Zealand Clinical 
Trials Registry, established in 2005, 
recently reached 10,000 trials 
registered. For each trial, information 
on the research plan, eligibility of 
patients, the drug or intervention, 
and much more, are available for 
anyone to view. Among its many 
benefits to researchers, clinicians and 
patients, the registry is a significant 
contributor to research transparency. 
Contributors to CTC successes
Patients, or study participants, have 
an essential role in all our trials. The 
CTC’s policies recognise the central 
place of participants in research. 
Patient representatives  are consulted 
when trials are being planned, often 
via a specific consumer advisory 
panel. We aim to communicate the 
results of trials to participants,and 
inform them of this commitment 
as part of the initial consent to 
participate in a trial.  
The NHMRC and other government 
entities continue to award 
substantial grants to the CTC in a 
highly competitive environment. 
The NHMRC program grant to 
the CTC’s collaboration with the 
Boden Institute enables important 
research studies to be integrated 
with trials funded from industry 
and other sources. We are grateful 
to our collaborators , among them 
the investigator networks, and 
funders, such as the pharmaceutical 
companies which provide almost 
half of our trials funding. 
CTC research and education 
achievements depend on over 200 
academic staff, professional staff 
and honorary associates. Their 
knowledge, experience, tenacity and 
representation in the wider clinical 
research community are behind our 
continuing successes.
National and international landmark trials
4 
 CLINICAL TRIALS CENTRE: 2014 RESEARCH REPORT 5
improving quAliTy of life AnD survivAl for people wiTh CAnCer
oncology trials
The CTC’s oncology group works in partnership with Australia’s leading cancer collaborative 
investigator groups. The CTC is the coordinating centre for the:
•	 Australasian Gastro-Intestinal Trials Group (AGITG)
•	 Australasian Lung Cancer Trials Group (ALTG)
•	 Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)
•	 Australia New Zealand Gynaecological Oncology Group (ANZGOG)
•	 Cooperative Trials Group for Neuro-Oncology (COGNO).
•	 and statistical centre for the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).
Through these groups, the CTC has links to other groups in Australia and internationally (see p.31). 
The oncology group coordinates trials of treatments for various cancers: gastrointestinal, lung, 
urogenital, gynaecological, brain and breast. Most trials are designed to answer a primary clinical 
question, such as whether one treatment is better than another. Treatments range across surgery, 
chemotherapy, radiation therapy and targeted agents, and more often are multidisciplinary 
treatments. However, the knowledge arising from a trial is much more: the data are applied to 
studies about health-related quality of life, cost-effectiveness of treatments, studies of tissue 
markers in individuals that predict their responses to specific treatment, and others.
The oncology group has grown rapidly in recent years to a team of over 50. Such a large group 
engaged with many colleagues around the world presents administrative challenges. In 2014, the 
management team was reorganised to form two streams—development and operations—with 
the aims of focusing on fast development of concepts into working protocols and maximising 
efficiency in trial operation. The group has also been working hard on increasing engagement 
and involvement with their many associates in investigator networks and at trial sites, including 
more streamlined web-based communications for training, initiation of trial sites, and access to 
documents and information. 
The group currently has over 60 trials in start-up, currently recruiting, or with patients in follow-
up. In 2014, the CTC’s oncology researchers published 35 articles in peer-reviewed journals and 
presented 60 studies at national and international conferences.
Burcu vachan, Oncology program manager
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The search is on for biological 
markers that will predict how 
well individual patients will 
react to different kinds of 
treatment. ultimately, patients 
can be given the treatment 
most likely to control their 
particular type of tumour and 
be spared treatments not likely 
to help them.
Sonia Yip, the CTC’s senior 
translational research fellow, 
provides scientific expertise in 
development of biological studies 
for clinical trials and works closely 
with all five collaborative groups. 
She also convenes workshops in 
concept development for trials and 
translational studies. 
Cancer biomarker studies lead to personalised treatment 
and better understanding of treatment targets
This is the age of personalised 
medicine: specific cancer therapies 
have been found to benefit some 
patients and not necessarily all, and 
patients respond to treatments to 
different degrees and in different 
ways. The search is on for biological 
markers that will predict how 
well individual patients will react 
to different kinds of treatment. 
Ultimately, patients can be given 
the treatment most likely to control 
their particular type of tumour and be 
spared treatments not likely to help 
them.
C017
Since the landmark findings of the 
CO.17 cetuximab trial in 2008, routine 
genetic testing of colorectal tumours 
for KRAS mutations can indicate 
which patients are unlikely to benefit 
from cetuximab treatment. These 
results were a major step forward for 
the treatment of advanced colorectal 
cancer and have been followed 
by many new questions. Why was 
cetuximab also ineffective for some 
of the patients in the group with 
nonmutated tumours? Is it because 
other biomarkers also affect their 
response to treatment? Analyses 
from the CO.17 trial population 
recently showed for the first time that 
another biomarker, epiregulin mRNA 
expression, also predicts whether 
cetuximab will improve survival.75 
iCECREAM
In ICECREAM, a current trial of 
cetuximab, potential trial participants 
with advanced colorectal cancer are 
screened to classify them according 
to genetic markers. Only those 
patients with tumours that are 
considered genetically susceptible to 
cetuximab are eligible for the trial. 
They are then randomly allocated 
to cetuximab alone or cetuximab 
with chemotherapy.259 The study will 
reveal whether cetuximab works best 
alone or with chemotherapy and will 
also provide high-quality data on the 
activity of cetuximab. Patients are 
being recruited from Australia, the 
UK, Spain and Italy.
iMPACT
Pancreatic cancer is a disease very 
much in need of new effective 
treatments. Most people with 
metastatic cancers of the pancreas 
do not survive to 5 years. Pancreatic 
tumours are biologically diverse, 
so a new approach is to group 
patients according to their molecular 
tumour type and use different 
targeted treatments depending 
on the type.126 The Individualised 
Molecular Pancreatic Cancer Therapy 
(IMPACT), is a trial assessing the 
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feasibility of such personalised 
treatment in patients with recurrent 
or metastatic pancreatic cancer.179,181 
IMPACT will test tumours for several 
molecular biomarkers with the aim 
of developing effective personalised 
treatment strategies. Patients will be 
randomised to standard gemcitabine 
chemotherapy or one of three 
targeted treatments, depending on 
the results of tumour testing. IMPACT 
is a multidisciplinary collaboration 
between Sydney Catalyst, the 
Australasian Gastro-Intestinal Trials 
Group, the Garvan Institute of 
Medical Research, which houses the 
Australian Pancreatic Cancer Genome 
Initiative (APGI), and the CTC. The 
pilot stage of the trial has been 
funded by Sydney Catalyst.
The importance of biomarkers in the 
trials of the CTC and its collaborative 
groups can be seen in the results now 
flowing from renal cell,187 lung44 and 
colorectal cancer trials.65,77,128,184 All 
these biomarker studies pinpoint the 
biological characteristics of patients 
that predict whether treatment will 
be individually worthwhile or not. 
They also increase knowledge about 
specific genetic and cellular processes 
and pathways that interact with 
treatments, leading the way for future 
research.
Benefiting patients through national  
and international brain cancer trials
The most common brain tumours of adults are gliomas.  
high-grade gliomas, including glioblastoma multiforme, are 
aggressive and difficult to treat and most patients live less than a 
few years. This type of cancer is therefore an important target for 
new and better treatments.
COGNO, the CTC’s newest cancer collaboration, is now well established, 
with an active trials program, a growing membership, and productive 
working relationships with various international research groups. COGNO’s 
main aim is to conduct investigator-initiated and collaborative group trials 
addressing important clinical questions in patients with brain tumours.
CABARET 
In 2014, COGNO−CTC completed its second trial of treatment for 
glioblastoma multiforme. The trial, CABARET, has tested bevacizumab, a 
monoclonal antibody that is known to improve patient outcomes in brain 
and other types of cancers. It targets a vascular endothelial growth factor 
(VEGF), thus attacking the blood supply nourishing the tumour. The trial 
is comparing bevacizumab alone with bevacizumab added to standard 
chemotherapy in over 100 Australian patients. The results of the trial will 
be published in 2015. 
In the second stage of CABARET, surviving patients are continuing to 
be followed up after their disease has progressed, with half of them 
randomised to continuing bevacizumab to see whether this leads to better 
outcomes than stopping treatment.
A recently published review of a similar question for the Cochrane Library 
found that, for people with newly diagnosed and recurrent glioblastoma, 
bevacizumab did not improve overall survival but prolonged the period 
that they remained well.79 Whether this situation makes a difference to 
quality of life remained unclear, underlining the need for more evidence 
from clinical trials. 
Dr Kathryn Field,  
CABARET study chair
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Does palliative chemotherapy improve symptoms  
in women with recurrent ovarian cancer? 
Most women with ovarian cancer have advanced-stage disease when their 
cancer is first discovered and most will develop recurrent disease. Many of these 
women are primarily concerned with relief of symptoms and improvement 
in quality of life, but most clinical trials focus more on tumour responses to 
chemotherapy and survival.
Symptom Benefit is an international collaborative trial attempting to address 
this inconsistency and lay groundwork for future trials. It is measuring the effect 
of palliative chemotherapy on symptoms suffered by women with ovarian 
cancer that has progressed after chemotherapy. Stage 1 of the study has 
aimed, first, to comprehensively describe the symptom burden, and second, 
to assess the how well symptoms are measured by current methods. With 
this knowledge, the investigators are constructing the optimal instrument for 
measuring subjective symptom benefit in trials of palliative chemotherapy for 
recurrent ovarian cancer. 
The first part of the study has been published.50, 80 The women reported pain, 
fatigue, abdominal bloating and discomfort, sleep disturbance, bowel problems, 
nausea and vomiting, shortness of breath, poor appetite, urinary symptoms, 
weight changes and emotional problems. Some symptoms mentioned by 
patients, such as anxiety and insomnia, were usually not reported by the 
doctors. The findings show how important it is to ask patients to rate their 
symptoms themselves. 
Embedded in this trial was the development of a general questionnaire 
instrument for measuring patient-reported outcomes, the ‘Measure of Ovarian 
Symptoms and Treatment’,80 which is being validated in stage 2 of the study.
Symptom Benefit, one of the ANZGOG-CTC trials, had its origin in a meeting 
in 2004 of the Gynecological Cancer Intergroup, the international network 
of investigators. The trial questions arose from discussion about gaps in the 
treatment of advanced ovarian cancer. It is now making a difference to many of 
the 200,000 women with a diagnosis of ovarian cancer each year.
‘It is time that patient-
reported quality of life 
measures and benefits be 
included as co-primary 
endpoints in the targets of 
clinical trials for patients 
with recurrent ovarian 
cancer.’
‘For most of these patients 
the aim of treatment is 
palliation. The primary 
endpoint of clinical trials 
has traditionally been 
progression-free survival, 
but arguably measuring 
the impact of treatment on 
symptoms for these patients 
is equally if not more 
important.’
Michael Friedlander, 
principal investigator 
for the Symptom Benefit 
study and member of the 
ANZGOG board of directors
improving quAliTy of life AnD survivAl for people wiTh CAnCer
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Continuing the work on improving survival  
after prostate cancer in two new AnZup trials
Prostate cancer is the most common cancer in Australian men and has become 
an important target for Australian research efforts.
Better detection and improvements in treatment driven by research evidence 
have increased survival over the past 20−30 years. Now, over 90% of men with 
prostate cancer survive for more than 5 years, but there are still about 3000 
deaths a year.
EZARAD and ENZAMET
ANZUP and CTC, in collaboration with international groups, have opened two 
trials of a new hormone therapy that promises to improve survival of men with 
prostate cancer—ENZARAD and ENZAMET.
In these trials a new second-generation nonsteroidal anti-androgen drug, 
enzalutamide, which blocks the action of male hormones, is being compared 
with a conventional anti-androgen drug. It is hoped that early use of 
enzalutamide will reduce residual androgen-receptor signalling that might 
promote growth of the tumour. 
In the ENZARAD trial, men with localised prostate cancer are receiving 
enzalutamide or a conventional anti-androgen drug for two years, during  
which time they also have 8 weeks of radiotherapy. It is expected to take two 
years to recruit 800 men, who will then be followed up after treatment for 
another 5½ years.
ENZAMET is attempting to prolong survival in men with prostate cancer that 
has spread after earlier treatment. The trial will have 1100 participants. Men 
will  be recruited from Australia, New Zealand, USA, Canada, UK, and Ireland. 
In both trials, tumour tissue and blood will be analysed to find biomarkers 
related to prognosis and that predict the effect of treatment in individual 
patients.
ENZARAD and ENZAMET
‘These two trials aim to 
answer the basic questions 
that patients and their 
doctors face every day in the 
clinic: what is the best way of 
treating men with prostate 
cancer?
They will be two of the 
largest trials in prostate 
cancer and people around the 
world are already intensely 
interested in them and what 
their outcomes might be.’ 
Professor ian Davis, 
co-chair of ENZAMET
xanthi Coskinas, development 
associate oncology program manager 
for ENZARAD and ENZAMET trials
10 
new treatments for gastrointestinal cancers
John Simes, AGiTG group coordinator, with Tim Price, chair of AGiTG
The CTC’s collaboration with AGITG 
initiates and conducts research 
into treatments for gastrointestinal 
cancers at locations from the 
oesophagus to the rectum. 
iNTEGRATE
In Australia, there are about 3,400 
new cases a year of cancer at the 
junction between the oesophagus 
and the stomach. This is treated with 
surgery and chemotherapy, with 
or without radiotherapy. There are 
no current proven treatments after 
failure of chemotherapy, and about 
2,400 people die each year. 
INTEGRATE is a trial of a promising 
new treatment, regorafenib, an 
inhibitor of enzymes involved in 
tumour growth. The drug is known 
to improve survival in patients with 
other gastrointestinal tumours. 
INTEGRATE recruited 152 patients 
across 54 centres in four countries, 
and was completed recently. Results 
will be presented and published in 
2015.
A LA CART
A La CaRT is a current trial 
determining whether laparoscopic 
surgery, or keyhole surgery, in 
the hands of qualified surgeons is 
equivalent to open surgery for rectal 
cancers in terms of the immediate 
effects of the surgery and longer-term 
recurrence, survival and quality of life.
Laparoscopic surgery has many 
advantages—a short time in 
hospital, smaller scars and fewer 
postoperative complications. It may 
be as good as open surgery in the 
long term. For rectal cancers, the 
advantages of laparascopic surgery 
over open surgery have not been 
reliably measured until now. This 
Australian-led trial will provide 
high-quality evidence of laparoscopic 
versus open rectal resection. The 
trial will also collect information 
on surgical complications, patient-
rated quality of life and long-term 
clinical outcomes. Standardisation 
of practices and training of surgeons 
are key parts of the trial, so it is also 
expected to improve the quality of 
rectal cancer treatment in Australia 
and New Zealand, an important extra 
benefit for these and future patients. 
RECENTLY COMPLETED TRiALS 
In 2014, several investigator-initiated 
gastrointestinal cancer studies 
conducted by the AGITG and the CTC 
were brought to a conclusion and 
results published or presented.103, 
184, 208, 247, 265, 266 Many of the new 
and current studies have been 
testing antibody treatments that 
target specific genetic pathways. 
These agents may be combined 
with chemotherapy or given if 
chemotherapy treatment has not 
stopped tumours from growing.
For example, TACTIC was a phase 
II trial in biliary tract cancer, a rare 
disease with a relatively low survival, 
usually treated with surgery. In 
this trial, panitumumab antibody 
treatment was added to the optimal 
standard chemotherapy. It was the 
first Australian trial selecting patients 
for expected treatment success on the 
basis of KRAS genetic status. TACTIC 
screened patients with biliary tract 
tumours and recruited 48 patients 
with KRAS wild-type tumours. The net 
clinical benefit of the combination 
treatment at 12 weeks was over 80%. 
The new antibody treatment was well 
tolerated and is promising, although 
this was a small, unrandomised 
trial and data on survival are still to 
come. The preliminary results were 
presented in late 2014.247
improving quAliTy of life AnD survivAl for people wiTh CAnCer
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AlTg is dedicated to reducing 
the incidence, morbidity 
and mortality of lung and 
other thoracic cancers and 
improving the quality of 
life of these patients, carers 
and families. The group 
is also taking the lead in 
establishing an international 
group to facilitate thoracic 
cancer research worldwide.
lung cancer, the leading cause of 
cancer deaths in Australia
Lung cancer is the fourth most common cancer and the leading cause of 
cancer death, killing over 8000 Australians in 2012. Over 60% of patients have 
advanced disease when it is found. New treatment options are needed. The 
ALTG-CTC collaboration completed two important lung cancer trials in 2014.
NiTRO
NITRO was a large phase III trial of giving patients nitroglycerin through a patch 
along with one of the standard chemotherapy regimens for advanced non-
small-cell lung cancer. Nitroglycerin is commonly used to dilate blood vessels 
and improve blood flow in heart patients. In the NITRO study, patients were 
randomly allocated to chemotherapy alone or chemotherapy with a patch. 
The biological rationale for the treatment was that nitroglycerin would lead to 
better delivery of the chemotherapy through improving blood perfusion and 
oxygenation and other potential mechanisms. The trial closed early after a 
median follow-up of 18 months, when an interim analysis showed that patients 
did not benefit.186
BR.26
Treatment options are needed for patients with advanced non-small-cell lung 
cancer after progression of their disease with standard chemotherapy.The BR.26 
trial investigated the effect of dacomitinib, a new oral antibody treatment. 
Patients on dacomitinib had a longer period without symptoms such as cough, 
breathlessness and pain, but also had more treatment side-effects. Overall, their 
survival was no better than for those on placebo. But the treatment did appear 
to improve survival in patients with a particular genetic marker, KRAS wild-type, 
indicating a direction for future research.44 
syDney CAnCer ConferenCe
John simes, CTC director, and 
sonia yip,oncology translational 
senior research fellow, with professor 
ian frazer, director of research at 
the Translational research institute 
in Brisbane, at the sydney Cancer 
Conference in november. sonia yip 
was co-convenor of the conference 
and ian frazer a keynote speaker. 
The conference covered T1–T3 
translational research: bench-to-
bedside and evidence into practice.
12 
Oncology clinical research fellows, Felicia Roncolato and Anne Long
Clinical fellows
The CTC’s collaborative oncology research program relies on the 
contributions of its clinical research fellows and clinical leads, most of them 
practising oncologists spending a period in their careers on research in 
areas of individual interest, including new treatments, clinical trial methods, 
meta-analysis and quality of life.
Research fellows and senior fellows share their clinical expertise and take the 
lead in developing overviews of current clinical evidence and therapy.They 
add value to the findings of clinical trials, developing new ideas, pursuing 
substudies, writing and presenting trial research and setting the CTC’s trials 
in the context of current health care.82, 126, 127, 128, 217, 243, 244
Research fellows are central to the quality, completeness and efficiency of 
the CTC’s integrated oncology research program.
Trials to reduce arm 
symptoms after 
surgery for early breast 
cancer (snAC)
New results from the SNAC breast 
cancer trial were published in 
October.149  1088 women with early 
breast cancer in Australia and New 
Zealand took part in the trial, which 
compared two methods of detecting 
whether their cancer had spread. 
Half had sentinel-lymph-node based 
management and half had routine 
axillary clearance of lymph nodes.
The women who had removal and 
examination of a sentinel lymph node 
had less subsequent arm swelling 
over 3 years than women who had 
the more invasive procedure.
In both groups, arm swelling 
increased over the first two years, 
but the women who had only the 
sentinel-node operation had a 
significantly smaller increase, about 
3% compared with about 6% for 
those who had the axillary clearance. 
The women’s arm movement was 
affected after the operation, epecially 
in the group having a full clearance, 
but it was almost back to normal after 
6 months and remained virtually 
unchanged on average over the 
3 years. 
Patients are still being followed up, 
and the analysis of 5 years of data will 
soon be published. The investigators 
have also been recruiting women 
with larger tumours and multiple 
tumours for the SNAC2 trial. The 
aim is to find out whether the risk of 
cancer recurrence is the same after 
sentinel-node biopsy as after full 
node clearance. If so, the sentinel-
node procedure will become standard 
practice for all women with low-risk 
early breast cancer. 
improving quAliTy of life AnD survivAl for people wiTh CAnCer
Katrin Sjoquist, CTC clinical 
lead for gastrointestinal and 
gynaecological cancer trials
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Trial participants have  
a central place in our clinical trials
Trials could not happen without the many patients who volunteer to participate. For many 
of these people, the motivation is altruistic. The trial treatment might not benefit them 
personally, but they know that the results may change treatment and help other patients in 
the future.
Trial patients have the reassurance that no matter which treatment they receive, they are 
getting the latest treatments and the best available medical care. In general, patients on trials 
do better than patients not on trials.
Consumer advisory panels (CAPs) are generally part of the organisational structure of each 
clinical trial, investigator group or collaborative group. They contribute to the planning and 
conduct of our clinical trials to ensure that the consumer perspective is incorporated from 
the time a trial is first planned until the final results are published. Consumer panels comprise 
people who have some connection with the disease area; they may have volunteered to 
take part in a trial in the past or had family experience with the illness in question. They may 
advocate for the patient group, identify gaps in research, contribute to clinical trial policy, 
advise on recruitment and retention of participants, review trial proposals, and contribute to 
developing documents and communications for trial participants to make sure that they will 
be understandable. They also bring their individual skills and insights to the whole process.
The CTC appreciates the commitment of trial patients. The groups at the CTC make particular 
efforts to provide participants with regular updates during long trials, and also to convey 
results to participants in language they understand.
TriAl pArTiCipAnTs
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Lucille Sebastian, manager of the  
PAEAN and APTS trials
preventing complications of 
preterm birth is an important 
theme in the CTC’s research 
program, which has included 
successful trials such as 
inis and BoosT ii, and 
international meta-analyses, 
such as pAris and neoprom. 
About a million babies 
worldwide are born before 
30 weeks each year. many 
die or face disability, with 
risks of neuromotor delay, 
low iq, sensory, learning, 
and behavioural problems, 
diabetes, and hypertension.
neonatal trials 
preventing adverse outcomes of neonatal  
hypoxic ischaemic encephalopathy (pAeAn)
The current standard treatment for infants deprived of oxygen during birth and 
suffering brain injury is controlled whole-body cooling. Even with treatment, 
up to half of these infants have permanent disabilities or die. Outcomes may 
be devastating for families and are costly for the health system so further 
treatments that can work synergistically with cooling and improve outcomes for 
these children are needed.
Erythropoietin, better known perhaps as a performance enhancer in competitive 
sport, works by different mechanisms from cooling and could lead to a further 
improvement in developmental outcomes, including cerebral palsy. PAEAN, 
a double-blind placebo-controlled trial to test this hypothesis, began in 2014. 
Full-term infants who show signs of brain damage immediately after birth are 
randomised to treatment with erythropoietin or placebo in addition to whole-
body cooling. Long-term improvements in child health are important, so these 
children will be assessed for development when they are 2 years old.
PAEAN investigators are also collaborating with the Cerebral Palsy Alliance and 
collecting further information on possible causes, predictors or preventions of 
cerebral palsy.
The investigators are cooperating with another trial group in the United States. 
The groups have agreed to harmonise their trial design and share data in a 
planned meta-analysis. If the results from both trials are positive, the evidence 
obtained is likely to translate into a rapid change in clinical practice worldwide.
Does placental transfusion prevent death and disability  
in very preterm infants?
The Australian Placental Transfusion Study (APTS) is an investigator-initiated 
study evaluating deferred clamping of the umbilical cord when infants are born 
more than 10 weeks early to improve blood flow to their brain and gut at the 
time of birth.
Current practice is to clamp the cord immediately after birth so that the infant 
may quickly be attended by a clinician. However, preterm infants are at risk of 
problems like anaemia and respiratory distress, which may lead to childhood 
disability. If the umbilical cord is left unclamped for a few minutes after the birth, 
some of the blood from the placenta passes to the baby (placental transfusion), 
increasing the infant’s blood volume and increasing blood flow to the lungs and 
other organs. 
The optimum time for clamping the cord is unclear 133 APTS has been 
established to answer this question. It is the largest ever randomised controlled 
trial of placental transfusion in very preterm infants. It will determine whether 
giving a placental transfusion at birth, by deferring clamping and cutting the 
cord, improves systemic blood flow and prevents ischaemia−reperfusion injury 
to the brain and gut and also reduces the need for donor blood, and thus 
ELISABETH SCHNEIDER/LOOK AT SCIENCES/SCIENCE PHOTO LIBRARY
A BeTTer fuTure for new Borns
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reduces sepsis, retinopathy, poor 
growth, mortality, morbidity and 
disability.
This group of babies are being 
followed up and will be assessed for 
disability up to 3 years of age. The 
follow-up assessments will use cost-
effective parent-report methods.
This large multicentre trial is 
recruiting infants from Australia, 
New Zealand, France, Pakistan, the 
United State and the United Kingdom 
and has recruited the largest number 
of participants in the preterm 
population of any study to date.
Preventing complications from 
preterm birth is an important theme 
in the CTC’s research program, which 
has included previous successful 
trials such as INIS and BOOST II, and 
international meta-analyses, such as 
PARIS and Neoprom. About a million 
babies worldwide are born before 30 
weeks each year. Many die or face 
disability, with risks of neuromotor 
delay, low IQ, sensory, learning, and 
behavioural problems, diabetes, and 
hypertension.
milk protein to reduce 
mortality in infants with low 
birthweight (lifT and leAp)
Preterm infants with very low 
birthweight are at high risk of 
infection and other problems, which 
may lead to childhood disability 
or death. They receive insufficient 
lactoferrin, an antimicrobial, 
antioxidant, anti-inflammatory 
iron-binding milk protein, from 
breast milk in their first month, 
resulting in suboptimal protection. 
The Lactoferrin Infant Feeding Trial 
(LIFT) is investigating whether adding 
lactoferrin to feeds for newborns 
at risk will reduce infection and its 
consequences. 
‘Iron sulphate is currently the 
standard first line of defence 
against anemia but it is 
suboptimal and has a host 
of negative side effects. For 
example, it is poorly absorbed, 
causes inflammatory problems,  
and poses a risk of accidental 
overdose and death in children if 
not safely stored.’
Lactoferrin, a natural  
protein found in breast  
and cow’s milk, in the treatment 
of iron deficiency anemia in 
pregnancy, could protect infants 
from a host of severe health 
problems.’
William Tarnow-Mordi,  
professor of neonatal medicine
 Alpana Ghadge, manager of 
the  LiFT and LEAP trials
LiFT 
LIFT Is an international investigator-
initiated Australian-led trial recruiting 
1500 infants from Australia, New 
Zealand and the United States. 
Parents have an integral role in the 
conduct of the study; they are part of 
the management group, help prepare 
study materials, promote recruitment, 
and disseminate results.
A cost-effectiveness analysis of the 
intervention and its outcomes is 
planned. The treatment is inexpensive 
and could potentially have benefit 
worldwide, even in countries where 
cost is a major consideration.
LEAP
The Lactoferrin Evaluation in 
Anaemia in Pregnancy (LEAP) trial 
aims to use lactoferrin to help infants 
through treatment of anaemia 
in pregnant women. Pregnant 
women can develop iron-deficiency 
anemia because of the growing 
fetus and the higher volume of 
blood circulating in a woman’s 
body. Anaemia is associated with 
preterm birth, low birthweight and 
developmental problems. The rate 
is 12% in Australia, but up to 40% in 
Indigenous Australians and over 50% 
in low-income countries. The current 
standard treatment is iron, which 
has common adverse side-effects, 
and although it corrects the mother’s 
anaemia, there is no evidence that 
it improves the outcomes for the 
infants. 
In the LEAP study, lactoferrin from 
cow’s milk will be compared with oral 
iron treatment, first to see whether it 
improves anaemia in women who are 
not pregnant. If it is safe and effective, 
it will then be given to pregnant 
women. The effect of treatment on 
the infant’s birthweight and iron 
levels will be assessed.
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‘These results resolve a major uncertainty about 
the value of treating women with statin therapy, 
and reinforce the need for recommendations to be 
included in national and international guidelines’.
Anthony Keech, 
co-coordinator of the 
international Cholesterol 
Treatment Trialists’ Collaboration
Anthony Keech and Jordan Fulcher,  
who led the CTTC study of statins  
for women
Cardiovascular trials
statin treatment reduces the risk of 
cardiovascular disease in women
In Australia more than 11,500 women die of a heart attack 
or stroke every year.
It has long been known that statin medications prevent 
cardiovascular events in people at risk. Women tend to 
develop cardiovascular disease later in life than do men, so 
have been underrepresented in most statin trials.
A large international meta-analysis by the Cholesterol 
Treatment Trialists’ Collaboration used the power of 
many studies combined to show conclusively that statin 
treatment reduces the risk of cardiovascular disease in 
women.
The research assessed the effect of statins in 46,675 
women and 127,474 men who had taken part in 27 
clinical trials, including the CTC’s LIPID trial (Long-Term 
Intervention with Pravastatin in Ischaemic Disease). It is 
the largest such database of statin trial data in the world. 
Overall, statin treatment reduced the risk of a major 
vascular event (heart attack, stroke, cardiac death, and 
the need for coronary revascularisation, stenting or 
bypass surgery) by 21% for each 1 mmol/L reduction in 
LDL cholesterol. The percentage risk reductions were 
similar in women and men, irrespective of any history of 
cardiovascular disease.
There has been a recent worldwide shift towards 
recommending treatment with statins to people without 
existing cardiovascular disease but with a sufficiently high 
risk of future disease. The results of this study will reassure 
doctors that these risk-based guidelines for treatment can 
be applied to men and women equally.
The study was an initiative of the Clinical Trials Centre and 
the Clinical Trial Service Unit & Epidemiological Studies 
Unit (CTSU), University of Oxford. The current meta-
analysis is one of a series of analyses of this data set, first 
planned in 1994.The work was funded by the NHMRC, 
the UK Medical Research Council (MRC), the British Heart 
Foundation (BHF), and the European Community Biomed 
Program.
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studies from the 
lipiD dataset
The Long-Term Intervention with 
Pravastatin in Ischaemic Disease 
(LIPID) study showed that statin 
treatment reduced the risk of a 
further coronary event in people 
with heart disease. Many years 
on from the main trial, the LIPID 
dataset of over 9000 patients is 
still answering questions about 
coronary heart disease.
The LIPID Australian and New 
Zealand investigators are 
collaborating with scientists 
from Germany, Sweden and the 
United States in studies of how 
molecular biomarkers are related 
to heart disease risk, and potential 
prediction of events by biomarker 
levels. 
A recent substudy showed that 
the baseline troponin level was an 
independent predictor of a higher 
risk of myocardial infarction and 
other cardiovascular events, such 
as heart failure and stroke.150 An 
increase in the troponin level in 
the first year of the trial was also 
associated with risk.
women with diabetes benefit from 
fenofibrate treatment 
Fenofibrate, available since the mid-1970s, is used to lower levels of blood 
fats (triglycerides) and small dense LDL or ‘bad’ cholesterol, and increase 
levels of HDL or ‘good’ cholesterol. High triglycerides along with high LDL is 
a common blood lipid profile in people with type 2 diabetes. 
The CTC’s FIELD study investigated the effect of fenofibrate treatment on 
prevention of cardiovascular events in nearly 10,000 patients in Australia, 
New Zealand and Finland. It was the first study to show that fenofibrate 
significantly reduced rates of diabetes complications such as eye and kidney 
damage and amputations.
In late 2014, the FIELD investigators completed a sex-specific analysis 
(of 3657 women and 6138 men with type 2 diabetes) and found that 
fenofibrate appears to be as effective in women as in men38. This new 
evidence is especially important for clinical practice because previous trials 
have either not included women or the numbers have been too small to 
generate meaningful results. 
Participants in the trial took 200 mg of fenofibrate daily for an average of 5 
years. The researchers found that fenofibrate reduced levels of adverse blood 
fats, total, LDL, and non-HDL cholesterol, and apolipoprotein B, more in 
women than in men, independent of menopausal status and whether they 
started taking statins. Fenofibrate reduced the risk of cardiovascular death, 
stroke, or a carotid or coronary revascularisation by 30% in women and 13% 
in men. The low rates of side-effects of fenofibrate were similar in men and 
women. 
‘The finding is good news for Australian women, who have a higher 
prevalence of cardiovascular disease than men. The study shows 
fenofibrate reduced the risk of dying from cardiovascular disease, or 
having a stroke or other adverse cardiovascular event, by 30 per cent 
in women and 13 per cent in men.’
Anthony Keech, chair of the FiELD trial
CENTRE JEAN PERRIN/SCIENCE PHOTO LIBRARY
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John Simes, Rebecca 
Mister, Adrienne Kirby 
and  Wendy Hague, 
CTC members of the 
iNSPiRE international 
steering committee. 
Wendy Hague, clinical 
trials program director, 
was also manager of the 
LiPiD study.
Aspirin lowers the risk of recurring 
blood clots in the inspire study ‘The treatment effect 
of aspirin is less than 
with warfarin or other 
new-generation direct 
thrombin inhibitors. 
But aspirin represents a 
useful treatment option 
for patients who are not 
candidates for anticoagulant 
drugs for anticoagulant 
drugs because of the 
expense or the associated 
increased risk of bleeding. 
Aspirin will be ideal in many 
countries where prolonged 
anticoagulant treatment is 
too expensive. This could 
mean a saving of millions 
of healthcare dollars 
worldwide.’
John Simes, 
chair of the iNSPiRE 
meta-analysis collaboration
A CTC international collaborative meta-analysis has provided clear, consistent 
evidence that low-dose aspirin reduces the risk of venous blood clots in people 
who are at risk because they have already suffered a blood clot125.
Most people who have had a blood clot in a leg vein (deep-vein thrombosis) or 
an embolism (where the clot blocks the blood flow) have anticoagulant drug 
treatment (such as warfarin) for at least 6 months, first to dissolve the clot and 
then to prevent it happening again. Long-term anticoagulant drugs require 
frequent regular blood tests and adjustments to the dosage. Also, there is a risk 
that the treatment could cause bleeding in some patients. For people who are 
not able to cope with this, the viable alternative of taking regular aspirin is a 
great benefit.
The results come from INSPIRE, a combined analysis of the CTC’s ASPIRE study 
and the WARFASA study in Italy. ASPIRE was completed in 2012 and showed 
that the aspirin treatment reduced the incidence of vascular events, but the 
number of patients was not suffiicient to estimate the effects of treatment on 
individual types of event or in subgroups of patients. 
ASPIRE had 822 participants from Australia, New Zealand, Singapore, India and 
Argentina, followed up for an average of 3 years, and WARFASA another 402 
patients followed up for at least 2 years.
The combined analysis showed that 100 mg aspirin a day compared with 
placebo reduced the risk of further blood clots in the veins by more than a third. 
Those with a higher risk, such as men and those at an older age, were more 
likely to benefit. Treatment was safe, with no significant bleeding associated 
with aspirin treatment
INSPIRE was planned and a protocol developed before the results of the two 
trials were known, a method that can provide the highest-quality, least biased 
evidence. This, in addition to the rigorous expert statistical analysis, vouch for 
the validity of these results.
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DiABeTes
what can be done about diabetes?
The prevalence of diabetes 
is increasing alarmingly 
throughout the world. it is 
predicted that in 15 years, 
340 million people will have 
diabetes. people with diabetes 
have a higher risk of heart 
attack, stroke, peripheral 
vascular disease, amputation, 
renal disease and eye disease. 
The factors that promote type 
2 diabetes—obesity, inactivity, 
smoking and others—also 
independently contribute to 
cardiovascular disease. The 
incidence of type 1 diabetes, 
which most often starts in 
childhood, is also increasing.
The CTC is part of worldwide 
efforts to understand the 
mechanisms of diabetes 
development and complications 
and improve the treatment of 
diabetes. its research covers the 
full pathway from molecular 
and genetic laboratory studies 
through the phases of clinical 
trials to delivery of clinical 
services for type 1 and type 2 
diabetes.
Diabetic retinopathy: new Centre for research excellence
Indigenous Australians with diabetes are at high risk of various complications, 
such as loss of vision and and kidney and cardiovascular disease. Optimum 
treatment requires coordinated care, and this can be challenging in rural and 
remote Australia.
A diabetes research team based at the CTC is setting up the collaborative 
virtual Centre for Research Excellence in Health Services Research to improve 
the health of Indigenous people in remote areas using modern electronic 
communication methods.
The main goal of the new centre is to detect potential diabetic eye disease early 
and streamline decisions on treatment to improve prevention, detection and 
treatment of vascular complications of diabetes.Teleretinal imaging will be used 
to assess risk of diabetic eye disease and cardiovascular disease. The telehealth 
service is expected to reduce the impact of chronic disease in Indigenous 
communities, reduce costs for health care associated with chronic diseases and 
reduce the health care disparity gap.
The new centre will have three main components:
1. Electronic decision support systems and retinal imaging software for 
managing diabetic eye disease, diabetes and cardiovascular disease 
embedded into local Indigenous health care facilities, with remote retinal 
picture reading, electronic referral and electronic reporting;
2. Shareable resources for administration, data registry and repository, 
biostatistics services and training of health professionals. These facilities 
will be accessible for new collaborative national and international diabetes 
research projects; and
Retinal pictures from the outback can be viewed in Sydney.  
Sven Erik Bursell and Alicia Jenkins at the CTC
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Anandwardhan Hardikar, head of  
the diabetes and islet biology group
3. training the next generation of 
doctor-researchers in Indigenous 
health by engaging postdoctoral 
fellows, PhD students and others 
to undertake clinical and research 
projects.
The new centre will integrate care 
for diabetes, eye disorders and 
cardiovascular disease for all life 
stages, build workforce capacity for 
high-quality health care delivery and 
research, develop new knowledge, 
build networks for guideline-based 
care, and expedite translation of new 
findings into practice and policy in 
Australia and other countries.
Members of the national research 
team are collaborating to share their 
vast experience and expertise in 
relevant areas of health care. They are 
research leaders in Indigenous health, 
diabetes, cardiovascular disease, 
ophthalmology, telehealth services 
and biostatistics.
The work is part of current efforts 
in the Northern Territory to develop 
a health information technology 
infrastructure to support diabetes 
management, funded by the NHMRC 
and the Fred Hollows Foundation.
potential prevention of 
diabetic eye disease and 
other disorders of small blood 
vessels
CTC’s completed FIELD trial, with 
nearly 10,000 patients, unexpectedly 
showed that fenofibrate slowed 
the development of disease of the 
small blood vessels, including eye 
and kidney disease, in people with 
type 2 diabetes. These results, and 
subsequent animal studies, have led 
to new ideas about the mechanisms 
of fenofibrate and other benefits it 
might have.
In the new FAME1-Eye trial, CTC 
researchers and their colleagues will 
be determining whether the benefit 
of fenofibrate in retarding diabetic 
retinal eye disease is similar in people 
with type 1 diabetes. Patients will be 
randomised to fenofibrate or placebo 
and followed up for 3 years with 
regular comprehensive assessments 
of their eye and general health. In 
parallel with the clinical study, CTC 
laboratory teams are investigating 
microRNAs, specific regulatory 
molecules that are markers of vascular 
damage in diabetes.
Daniel Calandro and Andrzej Januszewski
DiABeTes
CenTre for reseArCh 
exCellenCe 
CollABorATion
•	 Anthony Keech, Alicia 
Jenkins, sven-erik Bursell and 
val gebski from the CTC
•	 Tim henderson, Alice springs 
hospital
•	 Alex Brown, south Australian 
health and medical research 
institute, university of 
melbourne
•	 Jamie Craig, flinders 
university
•	 louise maple-Brown, 
menzies school of health 
research
•	 Kerin o’Dea, university of  
south Australia
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‘Living with type 1 diabetes is 
extraordinarily challenging, 
requiring the acquisition 
and maintenance of a 
complex set of practical 
skills and the ability to 
manage the behavioural 
and psychological impacts 
of having a chronic medical 
condition. Engaging with, 
supporting and learning 
with and from people with 
type 1 diabetes are central to 
delivering quality care. The 
skills are complex and not 
necessarily intuitive.’ 
Alicia Jenkins, 
professor of diabetes and vascular 
medicine at the CTC, and head of 
the CTC’s diabetes research 
Sarang Satoor, Wilson Wong, Mugdha Joglekar and Anandwardhan Hardikar,  
diabetes and islet biology group
In both type 1 and type 2 diabetes, 
genetic and environmental factors 
influence the risks of developing 
small-blood-vessel disease, but how 
these factors interact is not well 
understood. FIELD LIFE, an extension 
of FIELD in the laboratory, is 
examining blood levels of microRNAs 
and DNA damage. Laboratory results 
and risk factors are being compared in 
2000 patients who participated in the 
FIELD trial.
The CTC is also leading a telehealth-
based initiative for diabetic 
retinopathy screening, cardiovascular 
risk assessment and patient 
education, with 600 Indigenous 
participants in the Northern Territory.
Cell replacement therapy for 
type 1 diabetes
InsulIn from the pancreas is essential 
for controlling blood glucose levels. 
In type 1 diabetes, an auto-immune 
disease, T cells and other cells attack 
the insulin producing cells of the 
pancreas, so people with type 1 
diabetes need an alternative source 
of insulin, usually through multiple 
daily injections. Transplantation 
of pancreatic cells is an effective 
temporary treatment for type 1 
diabetes, but not feasible for all 
patients with type 1 diabetes because 
donor pancreatic cells are scarce. 
Embryonic cells, adult stem cells and 
other cell types are being considered 
as an alternative source of insulin.10
The CTC’s Diabetes and Islet 
Biology group are leading research 
to understand the molecular and 
genetic processes involved in insulin 
production and to find ways of 
increasing insulin gene expression in 
tissues other than the pancreas. In 
work so far on cells from mice and 
humans with diabetes, the group has 
found that gallbladder epithelial cells 
can produce insulin. They have shown 
that gallbladder cells have promise as 
an alternative to pancreas, are readily 
available and can be grown in the 
laboratory.
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reCruiTmenT To The 
T4Dm DiABeTes sTuDy
The T4Dm study is 
investigating whether adding 
testosterone treatment to a 
diet and lifestyle intervention 
can reduce the risk of type 2 
diabetes in men at high risk 
of developing diabetes due to 
overweight, low testosterone 
and impaired glucose 
tolerance. 
To enrol 1500 study 
participants, it was estimated 
that 24,000-30,000 men need 
to be screened, a recruitment 
challenge. Approaches to 
maximising the number of 
men screened ranged from a 
major national media launch 
on state-based and national 
Tv to grassroots promotion 
at local shopping centres and 
workplaces, as well as social 
media.
 The T4Dm group reviewed the 
recruitment strategies used 
in the first year and presented 
their results to the society 
for Clinical Trials.173 in the 
first year, over 13,000 unique 
visitors visited the website 
and 28% went on to access 
the screening questionnaire, 
most doing so within 2 weeks 
of the initial media launch. 
others heard about the study 
from subsequent mainstream 
media stories. mass media 
was the most effective tool, 
with grassroots approaches 
delivering relatively small 
returns for effort.
www.diabetesprevention.
org.au
The CTC’s T4DM trial coordination team, Caitlin van Holst Pellekaan  
and Sandra Healey, with trial manager Karen Bracken
professional diabetes education advanced by two new books
An important new book for diabetes clinicians and 
scientists, Lipoproteins in Diabetes Mellitus, details 
the many changes wrought by insulin resistance and 
diabetes mellitus on lipid and lipoprotein metabolism. 
The editors have brought together a panel of 
international diabetes scholars to describe in detail the 
place of vascular complications of diabetes and the 
ways of studying and treating them. The lead editor of 
the book, Professor Alicia Jenkins, says
‘It is our sincerest hope that the clinicians who care 
for patients with insulin resistance and diabetes 
mellitus and the basic science researchers who explore 
mechanisms of vascular damage and protection will 
find this treatment of the issues covered herein timely and relevant and that it 
will significantly impact patient care in a positive and lasting way.’
Alicia Jenkins is chair of the working group for Enhancing your Consulting Skills, 
an education resource for trainees in adult endocrinology and other interested 
health professionals. This resource has been published by the National Diabetes 
Services Scheme and Diabetes Australia, with lead author, Dr Jennifer Conn. It 
has already had several print runs.
The book teaches techniques that healthcare professionals can use to help 
people with type 1 diabetes develop the cognitive, practical and social skills 
that enable them to optimally self-manage their chronic medical condition 
in everyday life. Mental health problems, like depression, anxiety and eating 
disorders are more common in people with diabetes. The book addresses the 
skills required to identify and respond to such mental health issues.
DiABeTes
Quality and leadership in clinical research  — 
best evidence, best policy, best practice 
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Breast cancer reviews in 
the Cochrane library
The Cochrane Library is the online 
resource of medical evidence 
accessible to clinicians and people all 
over the world. It allows clinicians to 
make informed treatment decisions 
and patients to receive optimal 
treatments. 
The Cochrane Breast Cancer Group, 
based at the CTC, develops Cochrane 
systematic reviews. The group 
coordinates a large team of medical 
and radiation oncologists, breast 
surgeons, statisticians and consumer 
advocates, who act as authors, 
editorial board members and referees. 
This multidisciplinary make-up 
helps to ensure that reviews cover 
aspects of treatment most relevant 
to patients. The group endeavours to 
disseminate review findings as widely 
as possible, and its work is used by 
clinical practice guideline developers 
such as Cancer Australia and the 
National Institute for Health and Care 
Excellence in the UK. 
In 2014, the group was rated as one 
of its best performers by Cochrane, 
acknowledging consistently high-
quality work. Reviews published by 
the group in 2011 or 2012 were cited, 
on average, nearly 12 times in 2013 
(impact factor 11.6). 
KEY COCHRANE REviEWS  
PuBLiSHED iN 2014
Reviews published in 2014: ‘Partial 
breast irradiation for early breast 
cancer’, ‘Trastuzumab-containing 
regimens for metastatic breast cancer’ 
and ‘Surgery versus primary endocrine 
therapy for operable primary breast 
cancer in elderly women’.
new procedures and 
technologies must  be 
shown to work so that 
patients receive effective 
treatment and public 
funding is not wasted. 
The health technology 
assessment team at 
the CTC undertakes 
systematic reviews of 
new procedures being 
proposed for public 
funding. These are major 
reports that aggregate 
and evaluate evidence for 
safety, effectiveness and 
cost-effectiveness. 
The medical services 
Advisory Committee uses 
evidence from systematic 
reviews to advise the 
minister for health.
‘We would like to take this 
opportunity to congratulate 
you on achieving consistently 
high standards in the reviews 
we have screened from [the 
group]’
Toby Lasserson, 
senior editor, 
Cochrane editorial unit
eviDenCe for prACTiCe AnD puBliC poliCy
reviews to ensure  
that new medical  
technologies are  
effective and  
affordable
As an example of evidence in action, 
in April 2014 the Medical Services 
Advisory Committee recommended 
a major change to cervical cancer 
prevention in Australia. It was 
recommended that  five-yearly 
testing for the human papilloma virus 
(HPV) replace the current two-yearly 
Pap tests for cervical cancer and 
that screening start at age 25 rather 
than  18. 
The decision was based on a 
systematic review by the CTC’s health 
technology assessment team with 
researchers at the University of New 
South Wales and clinical experts. They 
had presented evidence to MSAC 
that the new HPV test would be 
more clinically effective and cost-
effective than the current test. Using 
it in screening is likely to reduce the 
occurrence of cervical cancer by at 
least 15%. 
Over the past twelve months, the 
health technology assessment 
team has also prepared two major 
assessments of the use of MRI and 
positron emission tomography 
imaging techniques to assist in 
surgery and treatment planning for 
women with locally advanced or 
metastatic breast cancer.
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further transparency of clinical trial information 
is an ongoing topic of concern and discussion 
among researchers, particularly those who 
undertake meta-analyses using data from 
individual patients in multiple clinical trials. 
how can trial data be shared responsibly and 
economically without violating research integrity 
or patients’ privacy? This was the subject of a 
recent article by the CTC’s head of systematic 
reviews and health technology assessment, lisa 
Askie, and her colleagues in government and 
industry.18
The AnZCTr’s 10,000th registered trial aims to  
improve mental health and coping of new parents
A new trial called ‘Baby Steps’ was the 10,000th trial to be registered on the 
Australian and New Zealand Clinical Trials Registry (ANZCTR), in operation 
since 2005 at the CTC. The trial is assessing a program of interactive internet 
and text messaging to help distressed new parents cope with baby care and 
improve their wellbeing. As an example of our registered trials, it reflects the 
reality that clinical trials are not just tests of drugs, but can look at many aspects 
of health care. 
This is a significant milestone for the registry. Registration of all clinical trials 
is important to health, as it is a way of disclosing all current research involving 
humans. It gives everyone the right to know what research is being done and 
whether any results might be missing from published science. 
The registry also improves the efficiency and value of trials research, by 
minimising duplication of research and reducing bias in the evidence used by 
medical professionals as a basis for choosing treatments.
There are trial registries in several countries, but the Australian registry was one 
of the first to be endorsed by the World Health Organisation. It has played an 
integral role in the worldwide initiative to make research information publicly 
available. With funding from the NHMRC and Therapeutic Innovation Australia, 
the registry is a valuable and free resource which enables patients and health 
professionals to access information about clinical trials taking place across all 
areas of health: new drugs, treatments, therapies, preventive measures, surgical 
procedures, lifestyle, rehabilitation strategies, complementary therapies and 
new medical devices. 
Data from the registry is also uploaded to other websites, such as the consumer-
friendly Australian Cancer Trials site. Access to such information helps patients 
find suitable trials, which ultimately contributes to better health outcomes for 
all Australians. The ANZCTR is freely available at www.anzctr.org.au
‘Clinical trials are the part 
of the research process 
through which consumers, 
governments and companies 
can be assured that new 
drugs, treatments and 
medical devices that are 
developed are effective  
and safe.
‘NHMRC believes in the  
value of registering clinical 
trials and promotes 
transparency in and the 
reporting of NHMRC-funded 
outcomes. Transparency 
helps to ensure accountability 
and high standards in 
research— which ultimately 
results in better outcomes for 
the beneficiaries of medical 
discoveries.’
Warwick Anderson, 
Chief Executive Officer, 
National Health and Medical 
Research Council
Ryan Sausa and  Kylie Hunter, ANZCTR 
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eviDenCe for prACTiCe AnD puBliC poliCy
epoCh research questions
•	 Do interventions implemented 
in the first year of life prevent 
obesity? 
•	 Do they influence weight  
status and behaviour at  
18-24 months of age? 
how can we prevent obesity in young children? 
Obesity in children, which is becoming more common, is thought to begin very 
early, depending on infant feeding practices, parents’ eating habits and other 
family factors. Metabolic and behavioural patterns are often established in the 
first few years of life.
There have been strong arguments for starting preventive action early. but there 
have been no published trials to guide the design, content and implementation 
of effective interventions that target infants. The Early Prevention of Obesity 
in CHildren (EPOCH) Collaboration is an Australian and New Zealand group 
conducting research into this question. 
The collaboration comprises  CTC experts in meta-analysis methodology and 
the investigators of four trials of obesity prevention strategies commencing 
before age 6 months. In general, evidence from randomised controlled trials 
can be more powerful when synthesised in an individual-participant-data 
prospective meta-analysis. In these analyses, the hypotheses, analysis methods 
and selection criteria are specified before the results of the individual trials are 
known. This method minimises publication and selection bias. Specific statistical 
techniques are used to account for differences between trials and missing data.
The EPOCH research plan is completely transparent and was in fact published in 
2010 before the analysis was done. Now the 2-year analysis has been completed 
and preliminary results were presented at the annual scientific meeting of the 
Australian and New Zealand Obesity Society in October.170 
Data were obtained from 2196 women and infants. Active interventions were 
moderately effective in reducing body mass index, prolonging breast feeding 
and reducing TV viewing, but did not affect sleeping patterns, physical activity, 
or the proportion of children who were overweight or obese. Further analysis 
will determine the longer-term effects of the intervention at 3.5 and 5 years 
of age.
The research has pushed knowledge boundaries 
in terms of the individual trials and the use of 
innovative analysis methods. The information 
obtained will guide decisions on investment 
in child health services to provide universal 
access to programs that are the most effective 
in reducing the prevalence of childhood obesity 
and associated harmful effects on health over 
the short and long term.
Kylie Hunter with Lisa Askie, head of 
CTC’s systematic reviews and health 
technology assessment group
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heAlTh eConomiCs
Deborah Schofield, professor, and leader 
of national health economics workforce 
studies
health economics
workforce studies
Keeping experienced, older workers 
in the labour force benefits the 
national economy, and thus is a 
concern to governments. Labour 
force participation is entwined with 
health status. CTC health economists, 
with their national collaborators, 
use Health&WealthMOD2030, an 
influential microsimulation model 
based on the Australian Bureau 
of Statistics Surveys of Disability, 
Ageing and Carers, to model health, 
labour force participation, personal 
incomes and savings, and so measure 
the economic impacts of ill-health 
leading to early retirement in 
Australia.
For example, diabetes is a national 
health priority and a common reason 
for early retirement. An economic 
modelling study estimated the overall 
dollar costs of diabetes at hundreds 
of millions.111 Better diabetes 
prevention would not only improve 
the health of the population but also 
the fiscal health of the country. In 
another modelling study, prevention 
of depression through group therapy 
was estimated to have economic 
benefits, with higher income for 
the individuals and a saving to the 
government of several million dollars 
in tax collected and expenditure 
avoided.142 
CTC health economists work 
with the Boden institute on 
weight loss research
Overweight is not just a health risk 
for the individual, but is a growing 
burden on health-care resources. It 
may be worthwhile for governments 
to subsidise weight-loss initiatives. 
To ensure that public funding for  
is not wasted, the costs and cost-
effectiveness of new interventions  
can be assessed within the framework 
of a clinical trial. 
The health economics team and 
the Boden Institute of Obesity, 
Nutrition, Exercise & Eating Disorders 
recently compared standard care by 
primary care providers  and referral to 
Weight Watchers for their economic 
potential.51 Although the cost of 
the Weight Watchers program was 
higher initially, in the long run, it led 
to greater weight loss at lower cost 
than standard GP care. The results 
of the study suggest that referral to 
commercial weight loss programs 
might be a highly cost-effective 
approach for doctors to consider for 
those at high risk of weight-related 
health problems, although outside 
the trial setting, the cost of such a 
commercial program would be borne 
by the individual, and in Australia, the 
cost of the primary practitioner would 
be covered by Medicare.
radiotherapy 
Intensity modulated radiation 
therapy (IMRT) is a new radiotherapy 
technique that allows a high radiation 
dose to the target tumour while 
minimising the dose to surrounding 
structures. It requires more resources 
initially and has longer planning and 
treatment times than the established 
alternative—conformal radiotherapy.  
An economic study under the 
auspices of the Trans Tasman 
Radiation Oncology Group (TROG) 
estimated the long-term effectiveness 
and cost-effectiveness of IMRT versus 
conformal radiotherapy for prostate 
cancer, accounting for quality of life, 
complications of radiation therapy 
and tumour control.28 IMRT was 
estimated to be both more effective 
and less costly overall than conformal 
radiotherapy, but differences were 
quite small and dependent on the 
assumptions used.
A problem with this (and assessment 
of rapidly evolving technologies 
generally) is that clinical trial evidence 
on the new treatment’s long-term 
effects would take years to gather, 
but evidence for funding decisions 
is needed now. The researchers used 
their best methods to extrapolate 
from the information available 
and used a decision analysis model 
with sensitivity analyses to reach 
conclusions that also highlight the 
areas where more evidence is needed. 
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Biostatisticians collaborate with international and national groups
‘The value of CTC 
biostatisticians is in providing 
clinicians not just with 
statistical results but also 
key concepts with respect to 
interpretation of study results 
and innovative study designs. 
They are a conduit between 
statistical methods and clinical 
relevance.’
val Gebski, 
professor of biostatistics
The CTC has been synonymous with methodological expertise in international 
trials and trial groups since 1988. CTC biostatisticians have long experience 
in leading the conception, design, analysis or interpretation of data in large 
complex studies conducted by national and multinational investigator groups.
For example, the CTC’s biostatistics group is the statistical centre for the 
European Network of Gynaecological Oncological Trial Groups (ENGOT), 
which brings together 19 trial groups from 14 countries. The collaboration is 
particularly relevant for academic clinical trials and can draw in international 
capability for translational research. A large dispersed group such as this is 
needed to recruit sufficient patients for research on rare diseases.
AuRELiA TRiAL
In 2014, CTC clinicians and biostatisticians led a substudy of the European 
AURELIA trial. It examined the important question of how adding the drug 
bevacizumab to chemotherapy affects symptoms and other aspects of quality 
of life for women with advanced ovarian cancer.129 Bevacizumab slows the 
growth of blood vessels and retards tumours, but has several side-effects. This 
study showed that the treatment did more than just delay the recurrence of 
the disease; it also improved quality of life, providing evidence for using this 
treatment in practice. 
ANZBCTG
The CTC has had a 27-year association with the Australia and New Zealand 
Breast Cancer Trials Group (ANZBCTG), as its statistical centre. The group 
recently published the main results of the NeoGEM trial, which found that a 
change to the chemotherapy regimen did not improve the the efficacy and 
safety of pre-surgery chemotherapy for women with locally advanced breast 
cancer.93
Biostatisticians beyond the CTC
Statistical methodology is a necessary aspect of most clinical research projects. 
CTC statisticians lend their expertise to research programs in other institutions 
in Sydney and elsewhere. For example, the group have worked with the 
emergency departments in Sydney hospitals and ambulance trauma teams in 
analyses supporting research to improve emergency services.37, 41, 83 Another 
series of studies involves methodological work with gynaecologists at Nepean 
Hospital to explore female pelvic organ prolapse across a range of aspects, from 
women’s perceptions of bother,136, 139, 141 through clinical assessment of the 
problem39 to predicting the success of repair surgery.106 These investigations are 
all different in terms of research question and design, requiring knowledge and 
versatility from the statistician.
meThoDology
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Biostatistics group. Back row: David Espinoza, Malcolm Hudson, Luke Buizen, Jodie 
Gonzalez Jennings, Elizabeth Barnes, Emma Gibbs, Lucy Davies, ian Marschner, Chee Lee, 
Rachel O’Connell, valérie Garès. Front row: Andrew Martin, val Gebski, Kirsty Mann, 
Mark Donoghoe
master classes in methodology
The biostatistics team run high-quality master classes, lasting between one 
day and a week, on a variety of statistical methodology topics. In 2014 they 
conducted a practical master class in time-to-event analysis, which covered 
sophisticated and complex techniques used to analyse follow-up data in 
clinical trials.
The statistical group is also involved in developing and delivering the critical 
appraisal component of the highly successful Basic Sciences in Oncology for 
oncology trainees for their professional clinical accreditation.
ian Marschner
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MASTER OF BiOSTATiSTiCS 
GRADuATE
patrick schober took the 
BCA program from the 
netherlands. his background 
is in anesthesiology and 
emergency medicine.
‘The BCA program allowed me to study next to my 
regular work at my own pace. The learning objectives 
are clear, units and course material are highly relevant, 
and online discussions with fellow students as well 
as excellent and timely feedback by instructors made 
studying biostatistics an enjoyable experience. I am 
proud of completing this program, which has provided 
the necessary skills to perform adequate analyses of 
medical research data.’
Patrick Schober
masters degree in clinical trials research
The CTC is at the forefront in knowledge and expertise in clinical trials. CTC’s 
researchers are well qualified to pass on their skills in a postgraduate program 
leading to formal qualifications in the design, conduct and interpretation 
of clinical trials. The Master of Clinical Trials Research program is taught by 
CTC academic staff and leads to degrees from the Faculty of Medicine at the 
University of Sydney.
Students complete the course with a solid understanding of research 
methodologies, clinical trials literature and the clinical trials process, including 
design, regulations, and statistical and ethical considerations.
The program is delivered 100% online, including lectures, discussion forums 
and supplementary notes. It is coordinated by Adrienne Kirby, Val Gebski and 
Anthony Keech.
‘This is an excellent course for anyone embarking on a career in clinical research. 
The comprehensive curriculum of trial design … provides a solid foundation for 
the planning and execution of clinical studies. It also adds a further layer of 
sophistication when analyzing and critiquing the current literature.’
Ru-Dee Ting, clinical research fellow, 
Department of Cardiology, St Michael’s Hospital, university of Toronto 
‘The Master of Clinical Trials Research program has provided me with an excellent 
scientific education for clinical research. It has … enabled me to pursue my goals 
without being confined to a rigid campus-based lecture schedule. I was able to 
manage my time and studies around running my private practice and yet still receive 
the regular support and feedback that I needed … Without this flexible, remote 
learning platform my research and PhD aspirations would not have been possible.’
Craig Moore, chiropractor in private practice
Biostatistics 
Collaboration of Australia
The BCA is an initiative of a 
collaborative group of biostatistical 
experts from around Australia. it 
has a postgraduate program in 
biostatistics by distance education 
provided by a consortium of seven 
Australian universities. in 2014, 314 
students were enrolled, 170 of them 
new in 2014, and 32 successfully 
completed their courses. The BCA 
coordinating office is supported by 
the CTC. 
The report for an external review of 
the program in 2014 concluded that 
‘The review panel found the BCA 
curriculum to be well-designed and 
keenly supported by stakeholders.’ 
in another evaluation, when 
the program was included in the 
university of Adelaide review of 
coursework studies in the schools of 
population health, medical sciences 
and medicine, it was alone in 
receiving a commendation.
CTC statistician elizabeth Barnes 
continues to coordinate and teach 
‘principles of statistical inference’, 
now co-coordinated by lucy Davies.
how an idea becomes 
a plan for a trial
one-day concept development workshops are a 
popular educational initiative of the CTC. These 
workshops help clinical and scientific investigators 
develop their ideas into a proposal for a clinical trial or 
translational research study. The investigators refine 
their idea into a suitable aim, objectives, population, 
interventions, study design, outcome measures, 
sample size, analysis plan and funding strategy, which 
can be used for a funding application and protocol.
eDuCATion
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CollABorATions
Collaborations
The CTC works with organisations around the world in collaborations that lead to better health 
outcomes in Australia and internationally. New collaborations are continually sought and then 
consolidated in research projects benefiting the health of Australians and others. 
GROuP NATuRE OF GROuP CTC ACTiviTY
ONCOLOGY iNvESTiGATOR GROuPS
Australasian Gastro-Intestinal Trials Group 
(AGITG)
Collaborative group for gastrointestinal cancer trials: Australia, New Zealand
international collaborations: Cancer Clinical Trials Unit Scotland (CACTUS), Eastern 
Cooperative Oncology Group (ECOG), European Organisation for Research and 
Treatment of Cancer (EORTC) , European Study Group for Pancreatic Cancer (ESPAC), 
Groupe Coopérateur Multidisciplinarie en Oncologie (GERCOR), National Cancer Centre, 
Singapore, National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) , 
National Surgical Adjuvant Breast and Bowel Project (NSABP), Medical Research Council 
(MRC), Oxford Clinical Trials Office, Oxford University (OCTO) , Pan-European Trials in 
Alimentary Tract Cancer (PETACC)
Coordinating centre 
and collaborator
Australasian Lung Cancer Trials Group (ALTG) Collaborative group for lung cancer trials: Australia, New Zealand
international collaborations: NVALT (Netherlands), NCIC CTG (Canada)
Coordinating centre 
and collaborator
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG)
Collaborative group for gynaecological cancer trials: Australia, New Zealand
international collaborations: Dutch Gynaecologic Oncology Group (DGOC), Group 
d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Gynecological 
Cancer Intergroup (GCIG), International Gynaecological Cancer Intergroup (IGCI), 
Gynecologic Oncology Group (GOG), Medical Research Council (MRC), Scottish 
Gynaecologic Cancer Trials Group (SGCTG)
Coordinating centre 
and collaborator
Australian and New Zealand Urogenital and 
Prostate Clinical Trials Group (ANZUP)
Collaborative group for cancer of the genitourinary system: Australia, New Zealand.
international collaborations: Cancer Research UK (CRUK), European Organisation for 
Research and Treatment of Cancer (EORTC), Groupe Coopérateur Multidisciplinarie 
en Oncologie (GERCOR),Institute of Cancer Research (ICR), National Cancer Research 
Institute (NCRI), Swedish & Norwegian Testicular Cancer Project (SWENOTECA), and 
Wales Cancer Trials Unit (WCTU)
Coordinating centre 
and collaborator
Australian New Zealand Breast Cancer Trials 
Group (ANZ BCTG)
Collaborative group for breast cancer trials: Australia, New Zealand
international collaborations: International Breast Cancer Study Group (IBCSG), Breast 
International Group (BIG), International Breast Cancer Intervention Study (IBIS)
Statistical centre 
for group, including 
randomisation
Cooperative Trials Group for Neuro-Oncology 
(COGNO)
Collaborative group for brain cancer trials: Australia
international collaborations: European Organisation for Research and Treatment of 
Cancer (EORTC)
Coordinating centre 
and collaborator
RACS-SNAC collaboration Collaboration with royal Australasian College of surgeons on snAC trials: Australia Coordinating centre 
and collaborator
Trans-Tasman Radiation Oncology Group 
(TROG)
Collaborative group: Australia and New Zealand Collaborator
COLLABORATiONS FOR META-ANALYSiS
Antenatal Magnesium IPD International 
Collaboration (AMICABLE)
Meta-analysis collaboration: international Collaborator
Cholesterol Treatment Trialists’ Collaboration 
(CTTC)
Investigators of cholesterol treatment trials: Australia, New Zealand, United Kingdom, 
United States, Italy
Coordination of 
meta-analyses in 
heart disease
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GROuP NATuRE OF GROuP CTC ACTiviTY
Cochrane Collaboration Breast Cancer Group Collaborative group undertaking systematic reviews of trial evidence: international Editoral base
Cochrane Prospective Meta-Analysis 
Methods Group
Collaborative group undertaking systematic reviews of trial evidence: international Coordinating centre
Cord Clamping and other Measures to 
Influence Placental Transfusion at Preterm 
Birth (CCPTP) 
Prospective meta-analysis collaboration: international Collaborator
Early Prevention of Obesity in Children 
(EPOCH) collaboration
Prospective meta-analysis collaboration: international Data coordination 
centre
INSPIRE (International Trials of Aspirin 
to Prevent Recurrent Venous Thrombo-
Embolism_
Meta-analysis: ASPIRE and WARFASA (Italy) Member
Meta-Analysis of Preterm Patients on Inhaled 
Nitric Oxide (MAPPiNO)
Meta-analysis collaboration: international Data coordination 
centre
Neonatal Oxygenation Prospective Meta-
analysis (NeOProM) collaboration
Prospective meta-analysis collaboration; international Coordinating centre
Perinatal Antiplatelet Review of International 
Studies (PARIS) collaboration
Meta-analysis collaboration:international Co-coordinating 
centre
Prenatal repeat corticosteroid international 
individual-patient-data study group: 
assessing the effects using the best level of 
evidence (PRECISE) collaboration
Meta-analysis collaboration: international Collaborator
Prevention of Ventilator Induced Lung Injury 
collaborative study group (PreVILIG) 
Meta-analysis collaboration: international Data coordination 
centre
Star Child Health Meta-analysis collaboration: international Member
OTHER COLLABORATiONS
Australasian Society of Thrombosis and 
Haemostasis (ASTH)
Professional group undertaking thrombosis trials: Australia, New Zealand Coordinating centre 
and collaborator
Australian Clinical Trials Alliance (ACTA) Advocacy body for investigator-initiated trials groups: Australia Founding member
Australian New Zealand Clinical Trials Registry 
(ANZCTR)
National register of clinical trials: Australia, New Zealand and international Coordinating centre
Biostatistics Collaboration of Australia (BCA) Universities undertaking postgraduate education in biostatistics: Australia Coordinating centre
Clinical Trials Transformation Inititative 
(CTTI)
Advocacy body for clinical trials: international Member
RNA-based Analysis for Prediction of Islet 
Death (RAPID)
Collaborative group: Australia Collaborator
Sydney Catalyst Consortium for translational research in cancer Collaborator
ORGANiSATiONS
Medical Services Advisory Committee 
(MSAC) and Department of Health and 
Ageing
Government: Australia Assessments of 
new technologies 
and other research 
services
Menzies Research Institute and Charles 
Darwin University
Research institution: Australia Collaborator 
CollABorATions
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CurrenT CTC TriAls
Current CTC trials
TRiAL PARTiCiPANTS TARGET ACCRuAL
NEONATAL DiSORDERS
Trials in start-up
LEAP: Lactoferrin evaluation in anaemia in pregnancy 
CTC-led study
Pregnant women with anaemia 900
PAEAN: Preventing adverse outcomes of neonatal hypoxic 
ischaemic encephalopathy 
CTC-led study
Newborn infants with signs of brain damage 300
Current trials
APTS: Australian placental transfusion study 
CTC-led study
Neonates born before 30 weeks’ gestation  1600 916
LIFT: Lactoferrin infant feeding trial 
CTC-led study
Infants born weighing under 1500 g 1100 143
Trials in follow-up
BOOST II: Benefits of oxygen saturation targeting 
CTC-led study
Neonates born before 28 weeks’ gestation  1200 1135
CARDiOvASCuLAR DiSORDERS
Current trials
Trials in follow-up
FIELD: Fenofibrate intervention and event lowering in 
diabetes  
CTC-led study
Patients with type 2 diabetes 8000 9795
LIPID: Long-term intervention with pravastatin in ischaemic 
disease 
CTC-led study
Patients with a history of coronary heart 
disease
9000 9014
DiABETES
Trials in start-up
e-PREDICE: Early prevention of diabetes complications in 
people with hyperglycaemia in Europe and Australia 
International study, BIONE and CTC
Adults with hyperglycaemia 100 (Australia);  
3000 (international)
FAME1-Eye: Fenofibrate and microvascular events in type 1 
diabetes 
CTC-led study
Adults with type 1 diabetes and 
nonproliferative retinopathy
450
Current trials
Performance of closed-loop artificial pancreas at home 
compared with best available technology 
St Vincents Hospital, Melbourne, JDRF, Medtronic, CTC study
People with type 1 diabetes 24
REMOVAL: Effects of metformin added to insulin on 
atheroma progression  
University of Glasgow and NHS-led, and CTC study
Adults with type 1 diabetes at risk of 
cardiovascular disease
90 (ANZ);  
500 (international)
60 (ANZ);  
429 (international)
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TRiAL PARTiCiPANTS TARGET ACCRuAL
T4DM: efficacy of adding testosterone to a lifestyle program 
to prevent progression to type 2 diabetes 
University of Adelaide and CTC study
Men with prediabetes and low testosterone 1500
TEAMSnet: using internet and mobile technologies for 
coordinated diabetes and heart  
University of Melbourne, Fred Hollows Foundation, AMSANT, 
CERA, CTC study
Indigenous people from remote and rural 
Australian communities
600 600
ONCOLOGY
Current trial
iTool: Evaluating a web-based tool for estimating and 
explaining prognosis 
CTC study
Patients with incurable cancer who attend 
clinics of participating oncologists and who 
want information about life expectancy
70 patients;  
70 oncologists
130 patients;  
28 oncologists
BREAST CANCER (COLLABORATiNG WiTH RACS)
Current trial
SNAC 2: Sentinel node biopsy versus axillary clearance 
RACS and CTC study
Women with operable breast cancer, 
stratified by factors including age and 
tumour size
 1012 
Trials in follow-up
SNAC 1: Sentinel node biopsy versus axillary clearance  
RACS and CTC study
Women with a single operable breast 
tumour <3 cm, stratified by factors including 
age and tumour size
1000 1088
GASTROiNTESTiNAL CANCER (COLLABORATiNG WiTH AGiTG)
Trials in start-up
ACTICCA-1: Phase III trial of adjuvant gemcitabine and 
cisplatin chemotherapy compared with observation 
AIO (Germany)-led, AGITG, and CTC study
Patients with biliary tract cancer after 
resection
440 (international)
CONTROL NETS: phase II open-label trial of lutetium-177 
octreotate added to capecitabine and temozolomide for 
neuroendocrine tumours 
AGITG and CTC study
Patients with pacreatic or midgut 
neuroendocine tumous
165
InterAACT: phase II open-label trial comparing cisplatin 
plus 5-fluorouracil versus carboplatin plus paclitaxel for anal 
cancer 
Cancer Research UK, AGITG and CTC study
Patients with locally recurrent or metastatic 
anal cancer
80 (international)
Current trials
ALT GIST: Imatinib alternating with regorafenib compared to 
imatinib alone for GIST  
AGITG, EORTC study
Adults with previously untreated metastatic 
gastrointestinal stromal tumours
240 0 (ANZ);  
0 (international)
ASCOLT: Aspirin for Dukes C and high-risk Dukes B colorectal 
cancers
National Cancer Institute (Singapore)-led, AGITG and CTC study
Patients with colorectal cancer who have 
completed surgery and other treatment
200 (ANZ);  
2660 (international)
21 (ANZ);  
550 (international)
DOCTOR: Phase II trial of preoperative cisplatin, 
5-fluorouracil and docetaxel with or without radiotherapy for 
oesophageal cancer 
AGITG and CTC
Patients with resectable adenocarcinoma 
of the oesophagus not responsive to 
chemotherapy
150 registered;  
60 randomised
104 registered;  
52 randomised
ICECREAM: Irinotecan cetuximab evaluation and cetuximab 
response evaluation among mutants 
AGITG- and CTC-led international study
Patients with Kras-WT metastatic colorectal 
carcinoma or a G13D mutation
100 81
 CurrenT CTC TriAls
 CLINICAL TRIALS CENTRE: 2014 RESEARCH REPORT 35
TRiAL PARTiCiPANTS TARGET ACCRuAL
IMPACT: Phase II trial using genomic sequencing and protein 
expression to direct first-line treatment  
Garvan, AGITG, CTC and Sydney Catalyst
Patients with metastatic pancreatic cancer 20 1
TOPGEAR: Randomised phase II–III trial of preoperative 
chemoradiotherapy versus preoperative chemotherapy for 
gastric cancer 
AGITG- and CTC-led international study
Patients with resectable gastric cancer 
suitable for these treatments
120 (stage 1);  
632 (stage 2)
120 (stage 1) 
35 (stage 2)
Trials in follow-up
A La CART: Australian phase III randomised trial of 
laparoscopy-assisted resection compared with open resection
AGITG and CTC study
Patients with primary rectal cancer 470 475
Adjuvant GIST: Adjuvant imatinib mesylate versus no further 
therapy after complete surgery (AG0403, EORTC 62024)
EORTC-led, AGITG and CTC
Patients with resected gastrointestinal 
stromal tumours (GIST) expressing KIT 
receptor
80 (ANZ) 85 (ANZ);  
946 (international)
Advanced GIST: Relation between dose and clinical activity of 
imatinib mesylate (AG0102, EORTC 62005) 
EORTC-led, AGITG and CTC
Patients with unresectable or metastatic 
malignant gastrointestinal stromal tumours 
(GIST) expressing KIT receptor
80 (ANZ) 116 (ANZ)
ATTACHE: Timing of surgery and adjuvant chemotherapy for 
hepatic colorectal metastases 
AGITG and CTC
Patients with confirmed resectable liver 
metastases and no other disease
200 8
CO.23: BBI608 and supportive care compared with placebo 
and supportive care for colorectal carcinoma  
NCIC-CTG-led AGITG and CTC study
Patients with advanced colorectal carcinoma 275 (ANZ);  
650 (international)
78 (ANZ);  
282 (international)
GAP: Phase II study of gemcitabine and NAB-paclitaxel for 
pancreas cancer 
AGITG and CTC 
Patients with resectable pancreas cancer 50 42
INTEGRATE: Phase II trial comparing regorafenib and placebo 
for oesophagogastric cancer 
AGITG and CTC -led international
Patients with advanced oesophagogastric 
cancer
150 152
LAP07: Multicentre phase III study of gemcitabine with or 
without chemoradiotherapy and with or without erlotinib  
GERCOR-led, AGITG and CTC
Patients with locally advanced 
adenocarcinoma of the pancreas
60 (ANZ);  
900 (international)
32 (ANZ);  
442 (international)
PETACC 6: Addition of capecitabine to preoperative 
oxaliplatin chemoradiotherapy and postoperative oxaliplatin 
chemotherapy for rectal cancer (AG0707R) 
EORTC (PETACC)-led, AGITG and CTC
Patients with locally advanced rectal cancer 135 (ANZ);  
1090 (international)
127 (ANZ);  
1094 (international)
Quasar 2: Phase III study of capecitabine and bevacizumab as 
adjuvant treatment of colorectal cancer (AG0107CR) 
OCTO-led, AGITG and CTC
Patients with colon cancer treated by surgery 120 (ANZ);  
1892 (international)
219 (ANZ);  
1952 (international)
REGISTER: Multicentre phase II study of risk evaluation in 
GIST with selective therapy escalation for response 
AGITG- and CTC-led international study
Patients with gastrointestinal stromal 
tumour not suitable for curative surgery
80 47
SCOT: Short-course oncology therapy, a study of adjuvant 
chemotherapy in colorectal cancer 
MRC-led, AGITG and CTC
Patients with fully resected stage III 
colorectal cancer
225 (ANZ):  
9500 (international)
213 (ANZ);  
6144 (international)
TACTIC: Phase II trial of panitumumab, cisplatin and 
gemcitabine  
AGITG and CTC
Patients with biliary tract cancer 45 48
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GYNAECOLOGiCAL CANCER (COLLABORATiNG WiTH ANZGOG)
Trials in start-up
ECHO: Exercise during chemotherapy for ovarian cancer 
ANZGOG and CTC study
Women with newly diagnosed ovarian 
cancer starting treatment
500
Current trials
ANZGOG-1103: Phase I–II BNC105P combination study 
ANZGOG- and CTC-led international study
Women with partly platinum-sensitive 
ovarian cancer in first or second relapse
Phase 1: up to 24 
(international)
15
ICON 8: Dose-fractionated chemotherapy compared with 
3-weekly chemotherapy for ovarian cancer 
MRC-led ANZGOG and CTC study
Women with ovarian, fallopian tube or 
primary peritoneal cancer.
145 (ANZ);  
1485 (international)
70 (ANZ);  
1566 (international)
Outback: Phase III trial of addition of adjuvant chemotherapy 
to standard chemoradiation as primary treatment for cervical 
cancer (ANZGOG-0902) 
ANZGOG- and CTC-led international study
Women with locally advanced cervical cancer 780 (international) 112 (ANZ);  
506 (international)
OVAR.21: Noninferiority phase III trial of bevacizumab + 
gemcitabine and carboplatin compared with bevacizumab + 
doxorubicin and carboplatin 
GCIG-led, ANZGOG and CTC study
Women with recurrent cancer sensitive to 
platinum-based treatment
654 (international) 48
PARAGON: Phase II study of anastrozole in gynaecological 
cancers (ANZGOG-0903) 
ANZGOG- and CTC-led international study
Women with potentially hormone-
responsive gynaecological cancers
 350 (international) 283 (international)
REZOLVE: Phase II study to evaluate the safety and potential 
palliative benefit of intraperitoneal bevacizumab 
DGOG-led, ANZGOG and CTC
Women with symptomatic ascites due to 
advanced chemotherapy-resistant ovarian 
cancer
26 11
Symptom benefit: Does palliative chemotherapy improve 
symptoms in women with recurrent ovarian cancer? 
(ANZGOG-0701) 
ANZGOG- and CTC-led international study
Women with platinum-resistant or 
platinum-refractory ovarian cancer
200 (ANZ);  
800 (international)
144 (ANZ);  
945 (international)
Trials in follow-up
CALYPSO: Phase III trial comparing pegylated liposomal 
doxorubicin and carboplatin vs paclitaxel and carboplatin 
GINECO-led, ANZGOG and CTC
Women with platinum-sensitive relapsed 
ovarian cancer
974 (international) 71 (ANZ);  
976 (international)
GOG182 
GOG-led, ANZGOG and CTC
Women with advanced stage (FIGO III-IV) 
epithelial ovarian or primary peritoneal 
carcinoma.
4200 (international) 184 (ANZ),  
4312 (international)
GOG199 
GOG-led, ANZGOG and CTC
Women at high risk of ovarian cancer 800 (international) 83 (ANZ),  
800 (international)
ICON 6: Safety and efficacy of cediranib in combination with 
standard chemotherapy 
MRC-led, ANZGOG and CTC
Women with platinum-sensitive relapsed 
ovarian cancer
400 (international) 17 (ANZ);  
486 (international)
ICON 7: Randomised trial of adding bevacizumab to standard 
chemotherapy 
MRC-led, ANZGOG and CTC
Women with epithelial ovarian cancer who 
have not received systemic antitumour 
therapy
1444 (international) 76 (ANZ);  
1450 (international) 
OVAR 16: Pazopanib versus placebo for ovarian cancer| 
AGO-led, ANZGOG and CTC
Women without disease progression 
after chemotherapy for epithelial ovarian, 
fallopian tube, or primary peritoneal cancer
900 (international) 65 (ANZ);  
940 (international)
PORTEC 3: Chemo radiation and adjuvant chemotherapy 
compared with with pelvic radiation alone in high-risk 
endometrial carcinoma 
ANZGOG- and CTC-led international study
Women with advanced endometrial 
carcinoma
120 (ANZ);  
670 (international)
122 (ANZ);  
688 (international)
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SCOTROC 4: Multicentre trial of carboplatin flat dosing vs 
intrapatient dose escalation in first-line chemotherapy  
SGCTG-led, ANZGOG and CTC
Women with ovarian, fallopian tube or 
peritoneal carcinoma who are unsuitable for 
platinum–taxane therapy
1300 (international) 64 (ANZ);  
937 (international)
Tarceva: Erlotinib after standard treatment for ovarian cancer 
(EORTC55041)
Women without disease progression 
after chemotherapy for epithelial ovarian, 
fallopian tube, or primary peritoneal cancer
830 (international) 41 (ANZ),  
830 (international)
TRIPOD: Phase II trial of intraperitoneal chemotherapy with 
paclitaxel and cisplatin (ANZGOG-0601) 
ANZGOG and CTC
Women with optimally debulked stage 
III cancer of the ovary, peritoneum and 
fallopian tube.
35–100 39
GENiTOuRiNARY CANCER (COLLABORATiNG WiTH ANZuP)
Trials in start-up
BL 12: Phase II trial comparing nab-paclitaxel with paclitaxel  
ANZUP and CTC study
Patients with metastatic urinary tract cancer 
and previous platinum therapy
199 (ANZ)
Pain Free TRUS B: Phase III trial of methoxyflurane with 
periprostatic local anaesthesia to reduce discomfort of 
transrectal ultrasound-guided prostate biopsy 
ANZUP and CTC study
Men scheduled to undergo first TRUS biopsy 
of the prostate 
420 (ANZ)
Current trials
BCG+MMC: Phase III trial of adding mitomycin C to BCG as 
adjuvant intravesical therapy for bladder cancer
ANZUP and CTC study
Patients with high-risk, non-muscle-invasive 
bladder cancer
500 22
ENZAMET: phase III trial of enzalutamide in androgen-
deprivation therapy for metastatic prostate cancer 
ANZUP and CTC study
Men with metastatic prostate cancer 1100 90
ENZARAD: phase III trial of enzalutamide in androgen-
deprivation therapy for localised prostate cancer 
ANZUP and CTC study
Men with high-risk localised prostate cancer 800 34
P3BEP: Phase III trial of accelerated versus standard BEP 
(ANZUP 1302) 
ANZUP, ANZGOG and CTC study
Patients with intermediate and poor-risk 
metastatic germ-cell tumours
Stage 1: 90 (ANZ); 
150 (international)
Stage 2: 350
4 (ANZ)
Trials in follow-up
Accelerated BEP: Feasibility study of accelerated BEP for 
advanced germ cell tumours 
ANZUP and CTC study
Patients with advanced germ-cell tumours Up to 50 45
Chemo & cognition: Cognitive function and treatment for 
testicular cancer (ANZGCTG 0106 
ANZUP and CTC study)
Patients being treated and followed up for 
testicular cancer
154 151
Eversun: Phase II trial of everolimus alternating with sunitinib 
for renal cell carcinoma (ANZUP 0901) 
ANZUP and CTC study
Patients starting first-line systemic therapy 
for advanced renal cell carcinoma
55 56
SORCE: Adjuvant sorafenib for renal cell carcinoma (RE 05) 
MRC-led, ANZUP and CTC
Patients with resected renal cell carcinoma at 
intermediate or high risk of relapse
 250 (ANZ);  
1656 (international)
168 (ANZ); 
1711 (international)
LuNG CANCER (COLLABORATiNG WiTH ALTG)
Trials in start-up
BR.31: Phase III study of adjuvant MEDI4736  
NCIC-led, ALTG and CTC
Patients with resected primary stage IB IB 
(>4 cm), II or IIIA non-small-cell lung cancer
200 (ANZ);
1100 (international)
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Trials in follow-up
BR.26: Phase III trial of PF-804 for non-small-cell lung cancer 
(ALTG 09/002) 
NCIC-led, ALTG and CTC
Patients with stage IIIB or IV non-small-cell 
lung cancer
180 88
B2P2M2: Phase II trial of BNC105P as second-line 
chemotherapy for pleural mesothelioma (ALTG 09/004) 
ALTG and CTC
Patients with pleural mesothelioma which 
has progressed after pemetrexed and 
platinum chemotherapy
 60 30
NITRO: Phase III multicentre trial of adding nitroglycerine to 
first-line chemotherapy for non-small-cell lung cancer (ALTG 
06/003) 
ALTG and CTC
Patients with advanced non-small-cell lung 
cancer
 500 372
PACT in NSCLC: Preferences for adjuvant chemotherapy in 
non-small-cell lung cancer 
ALTG and CTC observational study
Patients, surgeons and oncologists 200 122
BRAiN CANCER (COLLABORATiNG WiTH COGNO)
Trials in start-up
VERTU: Veliparib, radiotherapy and temozolomide in 
unmethylated MGMT glioblastoma 
COGNO and CTC
Patients with newly diagnosed resected 
glioblastoma with unmethylated MGMT 
promoter gene
120
ACED: Phase II study of acetazolamide + dexamethasone v 
dexamethasone alone for cerebral oedema 
COGNO and CTC
Adults with recurrent or progressive high-
grade glioma, who require dexamethasone 
or dose increase for cerebral oedema
84
Current trials
CATNON: Phase III trial of concurrent and adjuvant 
temozolomide chemotherapy for anaplastic glioma (EORTC 
26053-22054) 
EORTC-led, COGNO and CTC
Patients with non-1p/19q-deleted anaplastic 
glioma
100 (ANZ);  
748 (international)
74 (ANZ);  
662 (international)
Trials in follow-up
CABARET: Phase II study of carboplatin and bevacizumab in 
recurrent glioblastoma multiforme 
COGNO and CTC
Patients aged 18 years and over with 
recurrent grade IV glioma after radiotherapy 
and temozolomide chemotherapy
122 (part 1);  
60 (part 2)
122 (part 1);  
48 (part 2)
SEED: Self-reported evaluation of the adverse effects of 
dexamethasone 
COGNO and CTC
Patients with brain tumours or brain 
metastases or advanced cancer using 
steroids
50 patients,  
50 caregivers
66 patients,  
66 caregivers
funding
CTC undertakes investigator-initiated trials in 
collaboration with academic partners or clinical 
trial groups. Studies supported by research grants 
from industry are published independently of their 
funders in order to uphold CTC’s core commitment 
to integrity and transparency in research.
● public grant  
 funding for trials
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● other public  
 grants
● grants from  
 foundations and  
 trusts
● other
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operations executive, scientific advisory and 
management committees; PI, BR26 trial
Associate Professor Paul Mitchell, ALTG 
scientific advisory and management 
committees, chair, operations executive, 
Dr Paul Nguyen, ANZUP
Professor Anna Nowak, COGNO scientific 
advisory committee, PI, CATNON trial 
Oei, JL, BOOSTII and TORPIDO2 trials
Dr Robert Padbury, AGITG
Dr Nicholas J Petrelli, AGITG
Associate Professor Timothy J Price, PI, 
PETACC6 trial (AGITG)
Dr Kushwin Rajamani, FIELD study
Dr David T Ransom, PI, SCOT and ARCTIC 
trials (AGITG)
Dr Danny Rischin, ANZGOG executive
Professor Mark Rosenthal, COGNO chair; 
COGNO operations executive, scientific 
advisory and management committees
Dr Gail Ryan, COGNO scientific advisory 
committee
Associate Professor Eva Segelov, PI, 
ICECREAM, QUASAR2 and SCOT trials 
(AGITG)
Dr Shomik Sengupta, ANZUP
Dr Catherine Shannon, OVAR 2.21 (ANZGOG)
Dr Jennifer A Shannon, PI, TACTIC trial 
(AGITG)
Dr Bernard M Smithers, Gastric trial (AGITG)
Dr Benjamin Solomon, ALTG scientific 
advisory committee, PI, BR24 trial
Dr Allan Spigelman, Sydney Catalyst
Dr Nigel A Spry, PI, LAP07 trial (AGITG)
Dr Andrew R Stevenson, PI, A La CART 
(AGITG)
Associate Professor David Sullivan, LIPID and 
FIELD trial management committees
Dr Christopher Sweeney, ANZUP
Associate Professor Niall Tebbutt, PI, ATTAX, 
ATTAX2, ATTAX3 and MAX trials (AGITG)
Associate Professor Damien Thomson, co-PI, 
Aprepitant trial (ANZUP) and ANZUP germ-
cell subcommittee
Dr Andrew Tonkin, BiomarCare, LIPID study 
chair
Dr Ben Tran, BL12 study (ANZUP)
Dr Paul Vasey, PI, SCOTROC4 trial (ANZGOG)
Dr Michelle Vaughan, ANZGOG executive, PI 
ICON6
Dr Euan Walpole, PI, SCOT trial (AGITG)
Dr Neil Wetzig, co-PI, SNAC trial
Dr Helen Wheeler, COGNO scientific advisory 
committee
Dr Louise Wigston (Nott), CO.23 trial (AGITG)
Associate Professor Nicholas Wilcken, 
Cochrane Breast Cancer Group
Dr Kathryn Williams, FIELD study
Dr Scott Williams, ENZARAD trial (ANZUP)
Professor Gary Wittert, PI, T4DM trial
Dr Desmond Yip, SCOT, ALT GIST (AGITG)
Professor John Zalcberg, AGITG chair
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sTAff ACTiviTies
ASPIRE and INSPIRE steering committees 
(chair)
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee, 
operations executive committee
Australian New Zealand Clinical Trials Registry 
(ANZCTR) policy advisory committee
Cochrane Breast Cancer Group editor
Cholesterol Treatment Trialists Collaboration 
(CTTC) (joint coordinator)
Cooperative Trials Group for Neuro-Oncology 
(COGNO) scientific advisory committee 
(deputy chair), management committee, 
operations executive
BOOST II and LIFT trial management 
committees (neonatal)
FIELD management committee, executive, 
and cost-effectiveness subcommittee
IMPACT trial management committee (co-
chair)
Kanyini GAP Polypill Study safety and data 
monitoring committee (chair)
LIPID management committee, executive, and 
biomarker subcommittee
Clinical Trials Centre management review 
committee and scientific advisory 
committee
SNAC trial management committee
Sydney Catalyst governing council and 
scientific advisory committee (director)
Trials associate editor
Anthony Keech
Australian Clinical Trials Alliance (ACTA) 
founding members
CAMELLIA-TIMI 61 executive committee 
(lead investigator)
Cholesterol Treatment Trialists’ Collaboration 
(CTTC) (joint coordinator and convenor)
Clinical Trials Centre research committee 
(chair)
FAME-1 diabetes trial steering committee 
(chair)
FIELD management committee (principal 
investigator and study chairman), and 
quality-of-life and cost-effectiveness, 
ophthalmology, and scientific substudies 
committees
Further Cardiovascular Outcomes Research 
With PCSK9 Inhibition in Subjects With 
Elevated Risk (FOURIER) executive 
committee
International Journal of Cardiology  
editorial board
LIPID study management committee and 
executive
National Health and Medical Research Council 
grant review panel
New South Wales state ethics committee
PLoS Medicine editorial board
REMOVAL trial steering committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
lisa Askie
AMICABLE, MAPPiNO, PARIS, PRECISE, and 
PreVILIG collaboration steering committees
Australian Clinical Trials Alliance network 
profiling expert working group
Australian New Zealand Clinical Trials Registry 
operational executive committee
BOOST-II trial management committee
Cancer Australia Australian cancer trials expert 
user group
Clinical Trials Centre research committee and 
neonatal executive committee
Cochrane Collaboration prospective meta-
analysis methods group (convener), 
neonatal collaborative review group, 
handbook advisory group and individual 
patient data methodology group
CONSORT-C, PROMPT and SPIRIT-C advisory 
committees
EPOCH and NeOProM collaborations, chair
German Clinical Trials Registry and Pan African 
Clinical Trials Registry scientific advisory 
committees
International Forum for Standards for 
Research in Children sample size and data 
safety monitoring subcommittee
NHMRC assigners academy, NHMRC 
Australian Clinical Trials website editorial 
panel, large-scale clinical trials grant review 
panel, national ethics application form 
advisory group, research translation faculty, 
scholarships review panel
PLOS ONE academic editor
staff activities
supervision of  
research degrees in 2014
Anthony Keech
Jordan Fulcher, Jason Harmer, Claudia 
Boubeta, Ming Pan 
lisa Askie
Jacquelyne Lam
michelle Cunich
Thomas Lo
val gebski
Alan Garner, Farnoush Noushi
Anandwardhan hardikar
Ryan Farr, Wilson Wong, Michael Williams 
Andrzej Januszewski
Daniel Calandro
Alicia Jenkins
Paul Benitez Aguirre, Erin Bell, Daniel 
Calandro, Yoon Hi Cho, Ben Inja, Joanne 
Lee, Ben Ma, Claudia Boubeta, Ming Pan, 
Jon Noonan, Harris Schlen, Karin Schwartz, 
Caroline Traill 
Chee lee
Amira Elmadahm
sally lord
Amira Elmadahm
Andrew martin
Deme Karikios
martin stockler
Lesley Chim, Deme Karikios, Michaela Smith, 
Puma Sundaresan
william Tarnow-mordi
Claudia Boubeta, Ming Pan
Degrees awarded in 2014
Matthew Chan, MB BS, FRACP, Master of 
Clinical Trials Research
Andrzej Januszewski, MD, PhD, Master of 
Clinical Trials Research
Ru-Dee Ting, Ru-Dee Ting, MB BS, FRACP, 
PhD, Master of Clinical Trials Research
external committees
John simes
Australia and New Zealand Breast Cancer 
Trials Group (ANZBCTG) scientific advisory 
committee
Australian Clinical Trials Alliance (ACTA) 
founding member and chair, governance 
working group.
Belinda Kiely, senior clinical research 
fellow in oncology, was awarded a 
Peter Bancroft prize from the university 
of Sydney in September for her PhD 
thesis, ‘Estimating and communicating 
prognosis in advanced cancer’.
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PRISMA-IPD reporting standard working 
group
Use of magnesium sulphate for preterm infant 
neuro-protection guideline development 
panel
World Health Organization International 
Clinical Trials Registry Platform advisory 
committee and best practice group
elizabeth Barnes
Biostatistics Collaboration of Australia 
teaching committee
Cooperative Trials Group for Neuro-Oncology 
(COGNO) scientific advisory committee
DOCTOR trial management committee 
(AGITG)
Outback trial management committee 
(ANZGOG)
Karen Bracken
BCG+MMC trial management committee
T4DM study steering committee
Jenny Chow
Cancer Institute NSW Neuro-oncology Group 
(NSWOG), Co-operative Trials Group for 
Neuro-Oncology (COGNO) operations 
executive, annual scientific meeting 
organising committee, Clinical Oncology 
Society of Australia (COSA) executive 
officers network and associated working 
groups
Alan Coates
Australasian Gastro-Intestinal Trials Group 
(AGITG), chair, independent data and safety 
monitoring committee,
International Breast Cancer Study Group 
(BCSG), co- chair, scientific committee,
xanthi Coskinas
Australian and New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP) 
operations and scientific advisory 
committee, ENZARAD and ENZAMET trial 
management committees
val gebski
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee 
and MAX, TOPGEAR, IMPACT, PAN-1, 
GAP, DOCTOR, ICECREAM and REGISTER 
trial management committees and group 
statistician
Australasian Kidney Trials Network advisory 
board
Australia and New Zealand Breast Cancer 
Trials Group (ANZ BCTG) scientific advisory 
committee, ELIMINATE, GALA, LATER, 
NeoGem and PROSPECT trial management 
committees, and group statistician
Australian and New Zealand Urogenital 
and Prostate Cancer Trials Group ANZUP 
scientific advisory committee and 
Accelerated BEP and EVERSUN trial 
management committees and group 
statistician
Australian New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee, CALYPSO trial 
management committee, PARAGON and 
OUTBACK trial management committees, 
and group statistician
Bevacizumab use in platinum-resistant 
epithelial ovarian cancer; GAS (Effect 
of Spinal versus General Anaesthesia in 
Neonates undergoing Hernia Repair); 
TO2RPIDO (Targeted Oxygenation in the 
Resuscitation of Premature Infants and their 
Developmental Outcome) safety and data 
monitoring committees
Biostatistics Collaboration of Australia 
steering committees
Crown Princess Mary Cancer Care Centre 
(Westmead) Radiation Oncology research 
committee
Laparoscopic Surgery versus Hysterectomy in 
Patients with Cervical Cancer (LACC) trial 
management committee
NSW Health Central Sydney Area ethics 
committee clinical trials subcommittee
SNAC and T4DM trial management 
committees
Trans Tasman Radiation Oncology Group 
(TROG) scientific committee, publications 
committee, and group statistician
Alpana ghadge
BOOST II, LIFT and LEAP trial management 
committees
Westmead international update management 
committee
wendy hague
ASPIRE, INSPIRE, and LIPID management 
committees (cardiovascular)
Australasian Gastro-Intestinal Trials Group 
(AGITG) trials operations committee and A 
La CaRT trial management committee
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) trials 
operations committee
APTS, BOOST II, LEAP and PAEAN 
management committees (neonatal)
SNAC 1 and SNAC 2 trial management 
committees
T4DM trial management committee
Anandwardhan hardikar
Islet Society, Stockholm, Sweden, vice-
president
Lifestyle Interactions in Fenofibrate and the 
Epigenome (FIELD-LIFE), co-investigator
NHMRC Grant Review Panel member for 
diabetes/ obesity/ stem cell panels, Project 
Grant Assigners Academy member, 
Translational Research Faculty member
Non-coding RNAs in Endocrinology ,  
editor-in-chief
RAPID study principal investigator
Pancreatic islet biology book editor, Springer 
series ‘Regenerative medicine’
Visiting faculty, Indian Institute of Science 
Education Research, Pune, India
Alicia Jenkins
Insulin For Life Australia, Insulin for Life global 
and Insulin For Life USA board member
International Diabetes Federation Life For a 
Child program board member
REMOVAL metformin study, co-principal 
investigator and Australian lead
TEAMSNET telehealth initiative principal 
investigator
Adrienne Kirby
APTS and BOOST II management committees 
(neonatal)
Combination Antibiotic Treatment for 
Methicillin Resistant Staphylococcus Aureus 
(CAMERA) trial management committee
Faculty of Medicine, University of Sydney 
postgraduate coursework committee
Improving Delivery of Secondary Prophylaxis 
for Rheumatic Heart Disease trial 
management committee
INSPIRE steering committee
LIPID management committee
Randomised Trial on Surgical Treatment for 
Otitis Media in children Living in Remote 
Australian Communities trial management 
committee
Royal Prince Alfred Hospital clinical trials 
(ethics) subcommittee
Chee lee
Genomic Cancer Clinical Trials Initiative 
(GCCTI)
Study of Olaparib Clinical Effect (SOLACE0 trial 
management committee
Ann Livingstone
Australasian Lung Cancer Trials Group (ALTG) 
operations executive and scientific advisory 
committees
Cancer Institute NSW Neuro-oncology Group 
(NSWOG)
Co-operative Trials Group for Neuro-Oncology 
(COGNO) operations executive and scientific 
advisory committees
sally lord
Protocol advisory subcommittee (PASC) for 
Medical Services Advisory Committee
European Federation of Clinical Chemistry 
and Laboratory Medicine test evaluation 
working group
NHMRC grant review panel member for 
clinical trials panel
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ian marschner
Australasian Gastro-Intestinal Trials Group 
(AGITG) independent data and safety 
monitoring committee
APTS trial independent data and safety 
monitoring committee
Biostatistics Collaboration of Australia 
steering committee
Kristy mann
T4DM trial management committee
APTS management committee
Andrew martin
Australian and New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP) 
scientific advisory committee
BCG-MMC, CHEST, EPOCH, EVERSUN, 
INTEGRATE, LEAP, LIFT, ONTRAC, P3BEP 
and ProCare trial management committees
Julie martyn
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee and operations 
executive committee
Danielle miller
Australasian Gastro-Intestinal Trials 
Group (AGITG) operations executive 
committee and IMPACT and TOPGEAR trial 
management committee
Sydney Catalyst operations committee and 
executive committee
rebecca mister
ASPIRE and INSPIRE management 
committees (cardiovascular)
rachel o’Connell
D-Health (a study of vitamin D and health) 
trial management committee
PARAGON and Symptom Benefit trial 
management committees (ANZGOG)
PAN-1, TACTIC and TOPGEAR trial 
management committees (AGITG)
PAEAN trial management committee 
(neonatal)
Kate sawkins
Cancer Institute NSW Neuro-oncology Group 
(NSWOG)
Co-operative Trials Group for Neuro-Oncology 
(COGNO) operations executive committee, 
and CABARET, CATNON and SEED trial 
management committees
Deborah schofield
Pain Australia advisory board
Australian Research Council College of Experts
Garvan Institute Centre for Clinical Genomics, 
strategic advisory board
Health Workforce Australia technical advisory 
group
International Health Workforce Collaborative
International Journal of Microsimulation 
health editor
NSW Ministerial Advisory Committee on 
Ageing
Sydney Health Policy Network steering 
committee
Westmead International Network for 
Neonatal Education and Research (WINNER 
Centre) advisory committee
lucille sebastian
Pharmacodynamic effects of the heat shock 
protein 90 (Hsp90) inhibitor AUY922 in 
high-risk, localised prostate cancer (HSP 
90 inhibitor study) trial management 
committee
IMPACT trial management committee 
(AGITG)
Interdisciplinary Maternal Perinatal 
Australasian Collaborative Trials (IMPACT) 
Network operational subcommittee
PAEAN trial management committee and 
APTS management committee and 
echocardiography substudy management 
committee (neonatal)
Katrin sjoquist
Australia Asia-Pacific Clinical Oncology 
Research Development (ACORD) workshop 
steering committee, alumni committee 
(chair), faculty member
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee and operations 
executive committee, Symptom Benefit and 
PARAGON trial management committees, 
REZOLVE co-chair
Australasian Gastro-Intestinal Trials Group 
(AGITG) scientific advisory committee and 
operations executive committee, Upper 
& Lower GI working parties, CONTROL-
NETS, IMPACT, TACTIC, INTEGRATE trial 
management committees (CTC clinical lead) 
and international trial management group, 
Genomic Cancer Clinical Trials Initiative 
(GCCTI)
martin stockler
Australasian Lung Cancer Trials Group 
(ALTG) scientific advisory committee and 
operations executive
Australia Asia-Pacific Clinical Oncology 
Research Development (ACORD) workshop 
steering committee (convenor)
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee
Australian and New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP) 
scientific advisory committee, operations 
executive and Accelerated BEP, Aprepitant, 
Chemo & Cognition and EVERSUN trial 
management committees
Cancer Council Australia national oncology 
education committee
National Health and Medical Research Council 
grant review panels for oncology
University of Sydney Faculty of Medicine 
oncology block committee (chair), EBM 
in GMP3/4 (chair), evidence-based 
medicine resource group, integrated clinical 
attachment committee and University of 
Sydney Medical Program cancer planning 
committee
Burcu vachan
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive
Australian and New Zealand Urogenital and 
Prostate Cancer Trials Group (ANZUP) 
operations executive
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) operations 
executive
Australasian Lung Cancer Trials Group (ALTG) 
operations executive
Cooperative Trials Group for Neuro-Oncology 
(COGNO) operations executive
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Anne-sophie veillard
ATTAX3 and NITRO trial management 
committee
Kate wilson
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive committee, 
scientific advisory committee and annual 
scientific meeting committee, and A La 
CaRT, ATTACHE, CONTROL-NETS, DOCTOR, 
ICECREAM, MAX, PETACC6, and QUASAR2 
trial management committees.
nicole wong
Australasian Gastro-Intestinal Trials Group 
(AGITG) and Australian and New Zealand 
Urogenital and Prostate Cancer Trials Group 
(ANZUP) operations executive committees, 
and ATTACHE, LAP07, SCOT, ATTAX 3, 
PAN1, TACTIC, and Accelerated BEP, 
Aprepitant, P3BEP, SORCE and EVERSUN 
trial management committees
sonia yip
ARCS Australia Annual Scientific Congress 
organising committee
Australasian Gastro-Intestinal Trials Group 
(AGITG) operations executive, scientific 
advisory committee and biological 
subcommittee, AGITG-NCIC-CTG correlative 
research committee, and ALT-GIST, 
ASCOLT, GAP, IMPACT, INTEGRATE trial 
management committees
Australian and New Zealand Urogenital and 
Prostate Group (ANZUP) scientific advisory 
committee, renal cell subcommittee, 
germ cell subcommittee, translational 
subcommittee, and EVERSUN, SORCE, 
ENZAMET and ENZARAD, P3BEP trial 
management committees, ENZAMET and 
ENZARAD translational research steering 
committee
Australia New Zealand Gynaecological 
Oncology Group (ANZGOG) research 
advisory committee and cervix working 
group, REZOLVE trial management 
committee.
Australasian Lung Cancer Trials Group (ALTG) 
scientific advisory committee
Sydney Cancer Conference 2014 co-convenor
Sydney Catalyst scientific advisory committee, 
operations executive committee and T1/T2 
working group
regular academic teaching
John simes
Decision analysis, Master of Public Health and 
Master of Medicine, University of Sydney
Anthony Keech
Royal Prince Alfred Hospital cardiology 
training, and clinical tutor
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Master of Clinical Trials, University of Sydney 
(coordinator)
lisa Askie
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney 
(co-coordinator)
Controlled clinical trials, Master of Public 
Health, University of Sydney
Critical appraisal of evidence, Master of Clinical 
Trials, University of Sydney
Evidence-based medicine in the clinical years, 
University of Sydney Medical Program
elizabeth Barnes
ACORD faculty
Principles of statistical inference, Biostatistics 
Collaboration of Australia (coordinator)
Statistical principles and clinical trials, Master 
of Clinical Trials Research, University of 
Sydney (coordinator)
Controlled clinical trials, School of Public 
Health, University of Sydney  
(co-coordinator)
mark Donoghoe
Basic sciences in oncology, Health Education 
and Training Institute
David espinoza
Critical appraisal of evidence, Master of Clinical 
Trials Research, University of Sydney
val gebski
Basic sciences in oncology, NSW Cancer 
Council
Controlled clinical trials, Master of Public 
Health and Master of Medicine, University 
of Sydney
Radiation oncology training, RACR trainees, 
Westmead Hospital, NSW Cancer Council
wendy hague
Project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials, University 
of Sydney
Deme Karikios
Decision analysis, Master of Public Health and 
Master of Medicine, University of Sydney
Evidence-based medicine in the clinical years, 
and Oncology and palliative care, University 
of Sydney Medical Program
Adrienne Kirby
Master of Clinical Trials, University of Sydney 
(course coordinator)
Trial design and methods, Master of Clinical 
Trials, University of Sydney (coordinator)
Chee lee
ACORD faculty
Global biomarker studies, Master of Clinical 
Trials, University of Sydney
sally lord
Biomarker studies, Master of Clinical Trials, 
University of Sydney
Decision analysis, Master of Public Health, 
University of Sydney
Kristy mann
Advanced systematic reviews, Master of 
Clinical Epidemiology, University of Sydney
Andrew martin
ACORD faculty
Decision analysis (coordinator) and Controlled 
clinical trials (coordinator), School of Public 
Health, University of Sydney
Interpretation of trial analyses (coordinator), 
Master of Clinical Trials, University of Sydney
rebecca mister
Project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials Research, 
University of Sydney
rachel o’Connell
Advanced trial design, Master of Clinical Trials, 
University of Sydney
Katrin sjoquist
ACORD faculty
Project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials, University 
of Sydney
martin stockler
Australia & Asia-Pacific Clinical Oncology 
Research Development (ACORD) convenor, 
and international steering committee 
workshop (chair)
Making sense of cancer clinical trials for NSW 
medical oncology trainees (convenor)
Clinical epidemiology for physician trainees, 
Royal Prince Alfred Hospital
Evidence-based medicine in the clinical years, 
(chair and coordinator), and Oncology and 
palliative care (block chair), University of 
Sydney Medical Program
Medical oncology clinical training, Royal Prince 
Alfred Hospital
Patient-based measures, Master of Medicine, 
University of Sydney (course coordinator)
Project management in clinical trials: 
development, leadership and problem 
solving, Master of Clinical Trials Research, 
University of Sydney
Anne-sophie veillard
Trial design and methods, Master of Clinical 
Trials, University of Sydney
sonia yip
Global biomarker studies, Master of Clinical 
Trials, University of Sydney (coordinator)
Problem-based learning in the clinical years, 
University of Sydney Medical Program
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publications
Books
1. Conn JJ, Silberberg CL, Hendriecks C, 
Nankervis AJ, Cheung NW, Jenkins AJ. 
Enhancing your consulting skills—supporting 
self-management and optimising mental 
health in people with type 1 diabetes. Canberra: 
National Diabetes Service Scheme; 2014.
2. Jenkins A, Toth PP, Lyons TJ. Lipoproteins in 
Diabetes Mellitus. New York: Springer; 2014.
Book chapters
3. Brady MF, Gebski v. Trial design: should 
randomized phase III trials in gynecological 
cancers be abandoned? In: Ledermann J, 
Creutzberg C, Quinn M, editors. Controversies 
in the Management of Gynecological Cancers. 
London: Springer; 2014. p. 263–284.
4. Jenkins AJ, Klein FL, Januszewski 
AS. Lipoprotein glycation in diabetes 
mellitus. In: Jenkins AJ, Toth PP, Lyons TJ, 
editors. Lipoproteins in Diabetes Mellitus. 
New York: Springer; 2014. 157–186.
5. Jenkins AJ, Kostner KM, Kostner GM. 
Lipoprotein(a): structure, metabolism, and 
pathophysiology. In: Jenkins A, Toth PP, 
Lyons TJ, editors. Lipoproteins in Diabetes 
Mellitus. New York: Springer; 2014. p. 141–155.
6. Keech A, Jenkins A, Gebski v. About 
randomised trials related to Lipoproteins in 
Diabetes Mellitus. In: Jenkins A, Toth PP, Lyons 
TJ, editors. Lipoproteins in Diabetes Mellitus. 
New York: Springer; 2014. p. 329–346.
7. Little PJ, Chait A, Januszewski AS, Bobik A, 
O’Neal D, Jenkins AJ. Emerging lipoprotein-
related therapeutics for patients with 
diabetes. In: Jenkins A, Toth PP, Lyons TJ, 
editors. Lipoproteins in Diabetes Mellitus. 
New York: Springer; 2014. p. 435–453.
8. Satoor SN, Patil DP, Kristensen HD, 
Joglekar Mv, Shouche Y, Hardikar AA. 
Manipulation and assessment of gut 
microbiome for metabolic studies. In: 
Singh S, Coppola V, editors. Mouse Genetics. 
New York: Springer; 2014. p. 449-469.
9. Williams MD, Wong W, Rixon A, Satoor SN, 
Hardikar AA, Joglekar Mv. Pdx1 (GFP/w) 
mice for isolation, characterization, and 
differentiation of pancreatic progenitor cells. 
In: Singh S, Coppola V, editors. Mouse Genetics. 
New York: Springer; 2014. p. 271–288.
10. Wong W, Joglekar Mv, Satoor SN, Sahu S, 
Parekh VS, Hardikar AA. Lineage-committed 
pancreatic progenitors and stem cells. In: 
Turksen K, editor. Adult Stem Cells. 2nd ed. 
New York: Springer; 2014. p. 339–357.
Journal articles
11. Ameratunga M, Pavlakis N, Gebski v, 
Broad A, Khasraw M. Epidermal growth 
factor receptor-tyrosine kinase inhibitors 
in advanced squamous cell carcinoma 
of the lung: a meta-analysis. Asia Pacific 
Journal of Oncology 2014; 10(3): 273–278.
12. Askie LM, Darlow BA, Davis PG, Finer N, 
Stenson B, Vento M, Whyte R. Askie LM, 
Darlow BA, Davis PG, Finer N, Stenson 
B, Vento M, Whyte R. Effects of targeting 
higher versus lower arterial oxygen 
saturations on death or disability in preterm 
infants [protocol]. Cochrane Database of 
Systematic Reviews 2014; (7): CD011190.
13. Barz T, Melloh M, Lord SJ, Kasch R, 
Merk HR, Staub LP. A conceptual model 
of compensation/ decompensation in 
lumbar segmental instability. Medical 
Hypotheses 2014; 83(3): 312–316.
14. Barz T, Melloh M, Staub LP, Lord SJ, Lange 
J, Merk HR. Increased intraoperative epidural 
pressure in lumbar spinal stenosis patients 
with a positive nerve root sedimentation sign. 
European Spine Journal 2014; 23(5): 985–990.
15. Barz T, Staub LP, Melloh M, Hamann 
G, Lord SJ, Chatfield MD, Bossuyt PM, 
Lange J, Merk HR. Clinical validity of the 
nerve root sedimentation sign in patients 
with suspected lumbar spinal stenosis. 
Spine Journal 2014; 14(4): 667–674.
16. Basu A, Jenkins AJ, Stoner JA, Thorpe SR, 
Klein RL, Lopes-Virella MF, Garvey WT, Lyons 
TJ, DCCT/EDIC Research Group. Plasma 
homocysteine and carotid intima-media 
thickness in type 1 diabetes: a prospective 
study. Atherosclerosis 2014; 236(1): 188–195.
17. Benitez-Aguirre PZ, Craig ME, Cass HG, 
Sugden CJ, Jenkins A, Wang JJ, Cusumano J, 
Hodgson LA, Lee K, Wong TY, Donaghue KC. 
Gender differences in retinal microvasculature 
through puberty in type 1 diabetes: are girls 
at greater risk of diabetic microvascular 
complications? Investigative Ophthalmology 
and Visual Science. 6 Dec 2014.
18. Berlin JA, Morris S, Rockhold F, Askie L, 
Ghersi D, Waldstreicher J. Bumps and bridges 
on the road to responsible sharing of clinical 
trial data. Clinical Trials 2014; 11(1): 7–12.
19. Beumer JD, Gill G, Campbell I, Wetzig 
N, Ung O, Farshid G, Uren R, Stockler 
M, Gebski v. Sentinel node biopsy and 
large (≥3 cm) breast cancer. ANZ Journal 
of Surgery 2014; 84(3): 117–120.
20. Birch SE, Kench JG, Takano E, Chan P, Chan 
AL, Chiam K, veillard AS, Stricker P, Haupt 
S, Haupt Y, Horvath L, Fox SB. Expression 
of E6AP and PML predicts for prostate 
cancer progression and cancer specific 
death. Annals of Oncology. 17 Sep 2014.
21. Boekholdt SM, Hovingh GK, Mora S, Arsenault 
BJ, Amarenco P, Pedersen TR, LaRosa JC, 
Waters DD, DeMicco DA, Simes RJ, Keech 
AC, Colquhoun D, Hitman GA, Betteridge DJ, 
Clearfield MB, Downs JR, Colhoun HM, Gotto 
AM, Jr., Ridker PM, Grundy SM, Kastelein JJ. 
Very low levels of atherogenic lipoproteins 
and the risk for cardiovascular events: a meta-
analysis of statin trials. Journal of the American 
College of Cardiology 2014; 64(5): 485–494.
22. Bowyer SE, Schofield DJ. The role of oncology 
nurse practitioners in current oncology 
practice and lessons for Australia. Medical 
Journal of Australia 2014; 200(7): 382–384.
23. Brakoulias V, Starcevic V, Berle D, Milicevic 
D, Hannan A, Viswasam K, Mann K. The 
clinical characteristics of obsessive compulsive 
disorder associated with high levels of 
schizotypy. Australian and New Zealand 
Journal of Psychiatry 2014; 48(9): 852–860.
24. Bruhn MA, Townsend AR, Lee CK, Shivasami 
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